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Trypanosoma brucei expresses two hexokinases (TbHK1 and TbHK2) that are 
98% identical at the amino acid level.  We previously found that recombinant TbHK1 
(rTbHK1) has hexokinase activity, while rTbHK2 did not, a finding attributed to 
differences in the C-termini of the proteins.  We found that the C-terminal tails of TbHK 
contained a novel motif specific for eukaryotic hexokinases found within the final helix 
of an ATP-binding domain. By altering the residues in the C-terminal tail of TbHK1 to 
resemble the residues found in TbHK2, we found that D454, F462, M466, and N469 
were essential to TbHK1 catalysis. Additionally, we found that TbHK1 residues I458 and 
V468 contributed to substrate specificity as variants at these residues had a decreased 
affinity for fructose.  
Here, we demonstrate that TbHK1 is essential to the bloodstream form of the 
parasite as RNA interference knockdown of the enzyme was lethal to the cell. Since 
TbHK1 is essential to the parasite, TbHK1 can be used as a target for drug development. 
Lonidamine, an inhibitor of tumor hexokinase, was shown to be an inhibitor of TbHK1 
and hexokinase activity in whole cell lysates with IC50 of 850 µM and 965 µM, 
respectively. Moreover, we found lonidamine was toxic to bloodstream form parasites 
(LD50 = 50 µM) and insect (procyclic) form parasites (LD50 = 180 µM). Overexpression 
of TbHK1 in the procyclic parasites provided protection from lonidamine treatment. 
We have also identified myristate as an uncompetitive inhibitor of TbHK1 (Ki = 
50 µM) that also disassembles the hexameric protein complex of TbHK into monomers. 
 iii 
Recombinant TbHK1 and TbHK2 can reassemble into hexamers upon removal of 
myristate, and oligomerization of TbHK1 with TbHK2 causes an increase in the 
hexokinase activity when compared to TbHK1 homohexamers. Surprisingly, assembly of 
TbHK2 with an inactive variant of TbHK1, S160A, resulted in an active complex. Given 
TbHK1:S160A is incapable of catalysis, our results indicate that TbHK2 is competent for 
hexokinase activity. Our studies have helped to improve our understanding of the 
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The African trypanosome, Trypanosoma brucei, is a unicellular parasitic 
protozoan that is responsible for African trypanosomiasis. Three subspecies of T.brucei 
are known to cause illness in mammals; two infect humans, T.brucei gambiense and 
T.brucei rhodesiense, while the third infects cattle, T. brucei brucei [3]. The parasites are 
spread via the tsetse fly (Glossina spp.), which naturally occurs only in sub-Saharan 
Africa. The disease is prevalent in 36 of the 52 countries in Africa, and nearly 60 million 
people are at risk (Figure 1.1). Recently, African trypanosomiasis has been labeled as a 
neglected and category 1 resurgent disease, meaning the disease is under-reported as it is 
found in rural areas, it disproportionately infects destitute populations [4], and there are 
no vaccines or suitable treatments to contain the disease. 
Human African trypanosomiasis (HAT) currently infects over a half million 
people with 50,000 fatalities per year. The impact of HAT on disability-adjusted life 
years (DALYs), a measure of the impact of premature death and disability on a 
population, is profound, as 1,598,000 DALYs are lost each year [3]. The impact on diet is 
also severe, as bovine African trypanosomiasis has devastated the ability for sub-Saharan 
Africa to sustain beef or dairy industries [3]. 
 T.b. rhodesiense, the subspecies found in eastern and southern African (Figure 
1.1), causes an acute infection in humans (a few weeks until death), while T.b. 
gambiense, of west and central Africa (Figure 1.1), causes a chronic infection (several 
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months to years prior to death). The two types of HAT manifest in two stages. In stage 
one, the patient acquires the infection from a tsetse fly taking a bloodmeal. In 
T.b.rhodesiense infected patients, the parasites proliferate at the site of the tsetse bite 
creating a trypanosomal chancre that is healed in 3-4 weeks. Parasites spread to the 
draining lymph node to reach the bloodstream, where they proliferate again. Stage one is 
characterized by undulating fever, headaches and malaise. Winterbottom’s sign is another 
indication of a stage one infection; this is a lymphadenopathy in the posterior triangle of 
the neck. The major difference between the stage one and stage two infections is the 
location of the parasite. In a stage two infection, the parasites move from the bloodstream 
 
 
Figure 1.1 Distribution of Human African trypanosomiasis in Africa. Dark blue areas represent the 
highest levels of disease prevalence. Decreasing intensities of blue are used to illustrate less prevalence, 
while white is used to show areas that are free of disease burden. The black line distinguishes the regions 
impacted by the two human pathogens. The figure was provided by a World Health Organization (WHO) 
Fact Sheet on African Trypanosomiasis.  
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to the cerebral spinal fluid. This final stage is typified by nocturnal insomnia followed by 
severe headaches, coma, and death [3].  
Currently, there is no vaccine to treat HAT and four drugs are licensed to treat 
HAT. Pentamidine and suramin are used to treat patients during stage one. Melarsoprol 
and eflornithine are used to treat patients in stage two. Stage two treatments often have 
toxic side effects. For example, Melarsoprol treatment causes death in 2-12% of the 
patients. Current initiatives are focused on using cocktails of anti-trypanosomatid drugs 
to lower the doseage and resulting toxic effects of the drugs [3]. 
T.b. brucei, the sub-species that infects cattle, causes a similar wasting disease in 
cattle called nagana. Nagana prevents the establishment of a beef and dairy industry in 
sub-Saharan Africa costing the countries of the region nearly four billion dollars per year 
[5]. Diminazene is the only drug being used to try to prevent the progression of disease in 
cattle, and it is unlicensed [3].  
Over the past half century, T.brucei has been studied as an important eukaryotic 
pathogen.These studies have revealed that the protozoan is a useful system for studying 
eukaryotic biology in general partly, due to the fact that T.brucei is amenable to 
laboratory study. Additionally, tools have been developed for molecular biology. They 
include inducible systems for RNA interference (RNAi) and protein expression, T.brucei 
can undergo homologous recombinant, there are well-established semi-defined media to 
cultivate parasites, and the parasite has a small, compact sequenced genome [6].  
This tool set has made it a useful eukaryote to study processes that are common to 
other eukaryotes. For example, the pathogen makes large numbers of lipid anchored 
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proteins, so it has served as a useful source to study the biosynthesis and structures of 
glycosylphosphatidylinositol (GPI) anchors [7]. Other findings that used T.brucei as a 
model system include RNA editing and trans-splicing [8, 9].  
In this review, I will discuss studies concerning the lifecycle and metabolic 
adaptation of the parasite. I will review current theories regarding the catalysis and 
regulation of hexokinases, a family of enzymes central to carbohydrate metabolism. 
Further, I will elaborate on research pertaining to hexokinases in Trypanosoma brucei. 
 
The Lifecycle of Trypanosoma brucei 
 Parasitic protozoa, as all organisms, must respond to their environment in order to 
persist, thus many have developed a strategy that employs a complex lifecycle to allow 
them to respond to the variety of conditions they experience. Trypanosoma brucei 
experiences environmental changes in the fly and mammal. Hence, T.brucei has 
developed a programmed response to regiment general metabolism, surface molecule 
expression, mitochondrial function, and cellular morphology in order to survive. 
Although T.brucei has a very complex lifecycle, this review will focus on the two stages 
of the parasite that can be cultured in the lab: the procyclic (fly) form (PF) and the 
bloodstream form (BSF) (Figure 1.2). The tsetse fly takes a bloodmeal from a mammal 
and transfers parasites preadapted for life in the mammal to the host. Immediately the 
parasite differentiates into a proliferative form, known as the long slender bloodstream 
form, (LS-BSF), and proceeds to the draining lymph nodes to enter the bloodstream.  
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During the first two hours of the mammalian infection, the parasite acquires a 
dense surface coat of 107 molecules of GPI-anchored variant surface glycoprotein  
 
(VSG)(Reviewed in [10]). The parasite requires the population to have regulated, ordered  
expression of antigenically distinct VSGs in order to evade the antibody response of the 
mammalian host. As illustrated in Figure 1.3, there is initially one immunodominant 
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Figure 1.2 A Simplified Lifecycle of Trypanosoma brucei with Stage Specific Primary 
Metabolites Parasites in the bloodstream of the mammal use glucose to fuel glycolysis as their sole 
means of ATP production. The bloodstream form has two forms. The rapidly dividing slender form 
parasites are shown in red. The nonproliferative short stumpy form, in lavender, are adapted for 
survival in the fly. Following uptake by a tsetse fly, the parasites differentiate into the procyclic form, 
blue. These parasites rely on amino acid metabolism, and they migrate from the midgut to the 
salivary glands. Here they undergo adaptation to prepare them for life in the mammalian bloodstream. 
Figure was adapted from [1]. 
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parasite population expressing a single VSG, for example VSG-A. The host raises 
antibodies to the specific VSG and subsequently kills the parasites that have that 
particular antigen. As the immunodominant population is dying, a second population 
expressing a different VSG proliferates, and that population replaces the dying population 
as the new immunodominant population. Again, the mammal raises antibodies to the new 
VSG, and kills the population; however, a new population of trypanosomes expressing 
another distinct VSG replaces the previous species. The cycle continues, and the 
undulating fever experienced in stage one trypanosomiasis is a result of this cycle. The 
parasite’s ability to express the >1,000 VSG genes is too much for the host’s immune 
 
Figure 1.3 Antigenic variation during African trypanosomiasis. A mammalian host is infected 
with a population of trypanosomes expressing a variety of their greater than 1,000 VSG genes. One 
population becomes immunodominant (VSG-A, black)  and provokes a humoral immune response 
from the host. As the first population is cleared, a second immunodominant population arises (VSG-
B, blue). It is cleared and replaced (VSG-C, red), and this process continues (VSG-D, green) until the 
host can no longer respond to the pathogen. Image was modified from [10]. 
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responses, and the parasite escapes the bloodstream and enters the CNS causing the death 
of the mammal.  
During the BSF parasite’s time in the mammal, the parasite relies exclusively on 
glycolysis, the oxidation of glucose to pyruvate, to generate ATP from the substantial 
amount of glucose (5 mM) in the mammalian bloodstream. This form of the parasite 
lacks an active mitochondrion, a tricarboxylic acid cycle, and an oxidative chain for 
respiration [1].      
After the parasites reach a specific density, a portion of the population of the 
parasites differentiates into the nonproliferative short-stumpy bloodstream form (SS-
BSF). The SS-BSFs resemble the LS-BSFs in many biological processes, save they have 
a shorter, rounder appearance and they lack the ability to divide. These parasites are 
considered to be adapted to survive in the fly, yet they do not possess a metabolically 
active mitochondrion.  
The fly takes a bloodmeal from an infected mammal and acquires the SS-BSF, 
which in the first two hours of the fly infection switches from a dense VSG coat to a less 
dense surface coat comprised of proteins dubbed procyclins. This switch is believed to 
coincide with the activation of the mitochondria, as expression of the major surface 
proteins is regulated by mitochondrial enzyme function [11] There are two major forms 
of procyclins, EP and GPEET, with names that correspond to the amino acid repeats in 
the proteins. EP, having glutamic acid and proline repeats, can be glycosylated and 
represent the dominant surface molecules during the early infection of the fly. GPEET 
(glycine, proline, glutamic acid, glutamic acid, threonine repeats) are unglycosylated and 
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found during the later stages of the midgut infection in the fly. Procyclins are essential to 
survival in the fly as knockouts of EP procyclin have resulted in a severe decrease in the 
parasite’s ability to establish infection in the intermediate host, while all but one copy of 
GPEET could be knocked out. [12].  It is important that the parasite carefully regulate 
surface molecule expression, as expression of procyclins in the mammal or expression of 
VSG in the fly could lead to clearance of the parasite from either organism [13]. It is 
believed that procyclins are necessary because they interact with a molecule called 
TsetseEP (a similar repetitive protein to TbEP procyclin) to help establish and maintain 
the fly infection [14].  
The PF trypanosomes differ from the BSF parasites in mitochondrial function and 
metabolism. The PF parasites rely primarily on amino acids for metabolism during the fly 
infection as glutamine, proline and threonine are the three most abundant metabolites in 
the hemolymph and tissue fluids of the fly [15]. Glutamine and proline are converted to 
α-ketoglutarate and processed to succinate, while threonine is metabolized to acetyl-CoA 
and converted to succinate via the tricarboxylic acid cycle to produce ATP. Subsequent 
electrons produced by oxidation of succinate to fumarate are used to fuel the oxidative 
chain of the mitochondria and generate ATP. The products of the tricarboxylic acid cycle 
can also be used by the parasite for gluconeogenesis to generate additional ATP and to 
produce sugars for structural purposes. Additionally, the parasite can also use lipid 
degradation as a source for metabolites [2].  
Although the parasite relies on amino acid metabolism in the fly, glycolysis is still 
very important to the PF parasite. Glucose can down-regulate proline metabolism, as cells 
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grown in the presence of glucose had decreased proline dehydrogenase activity [16]. 
Further, the cells exhibited decreased proline uptake, and cells grown in proline were 
sensitive to 2-deoxy-D-glucose. The rapid inhibition of glycolysis is fatal to procyclic 
parasites. For example, treatment of PF cells with tubercidin, an inhibitor of the 
glycolytic enzyme phosphoglycerate kinase, is detrimental to parasites grown in glucose 
rich media; however if the parasites are permitted to adapt their metabolism in low 
glucose media, they are less sensitive to tubercidin [17]. A similar phenomenon was 
noted with respect to silencing glycolytic enzymes. Silencing pyruvate kinase (TbPK) in 
cells grown in glucose-rich media was fatal, but if the parasites were permitted to adapt in 
low glucose media, PK depletion was not detrimental to the cell [18]. These results 
suggest that PF may have a flexible metabolism but prefer glycolysis. 
Following the mid-gut infection, parasites make their way to the salivary glands 
via a poorly described pathway. Once in the salivary glands, the parasite differentiates 
into a form pre-adapted for life in the mammal, called the metacyclic form. The 
metacyclic form of the parasites are nonproliferative and reside in the salivary glands. 
They develop biological aspects and processes to permit survival in the mammalian host, 
including VSG expression and repressed mitochondrial function [1]. 
Glycosomes: Unique metabolic organelles of kinetoplastids 
One of the most unusual aspect of the cell biology of T.brucei and other 
kinetoplastids is the presence of peroxisomes-like microbodies known as glycosomes. 
Glycosomes house enzymes that catalyze the first seven reactions in glycolysis (amongst 
other proteins) (Figure 1.4). Because the parasite’s metabolism is compartmentalized, 
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enzymes in the cytosol, mitochondria, and glycosomes must act in concert to allow for 
the rapid metabolic adaptation that is required during parasite development between 
mammal and tsetse fly. One example of the gross change in glycosomes related to the 
environmental change is that the glycosome number remains unchanged between BSF 
and PF trypanosomes, but the concentration of glycolytic enzymes in the glycosome 
decreases during differentiation from BSF to PF trypanosomes [19].    
Glycosomes are considered specialized peroxisomes as they share many 
biosynthetic components and structural similarities. Both are single membrane-bound 
organelles with a very dense protein matrix that exhibit low permeability to small 
molecules (ATP, NAD/NADH, and acetyl-CoA) [20]. Additionally, both contain 
enzymes required for beta-oxidation of fatty acids, isoprenoid metabolism, and ether lipid 
biosynthesis [2, 21]. However, the incorporation of glycolytic enzymes into  
the glycosome is unique to kinetoplastids. Another notable difference is the ability of 
peroxisomes in most organisms is to break down hydrogen peroxide produced by beta-
oxidation to water and oxygen, a reaction completed by the enzyme catalase. Catalase is 
absent in kinetoplastid glycosomes, except for the non-pathogenic Crithidia spp. It is 
theorized that trypanosomes (T.brucei and T.cruzi) use glycosomal glutathione-dependent 
peroxidase to remove glycosomally generated hydrogen peroxide [22, 23, 24].  
Proteins are transported into glycosomes differently than into other organelles. 
While the mitochondria and ER unfold proteins during protein translocation, peroxisomal 
proteins are incorporated as native folded proteins by a specialized peroxisomal receptor 
and incorporation complex [25]. Similar to other eukaryotes, members of the PEX family 
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of proteins have been found to be essential for glycosome and peroxisome function, 
biogenesis, and protein transport in T.brucei, kinetoplastids and other eukaryotes [2, 26, 
27]. PEX14 has been implicated in the receptor complex of T.brucei, which recognizes a 
signal sequence at or near the N-terminus of the polypeptide [28]. There are two types of 
peroxisomal targeting sequences (PTS); the well defined PTS-1 sequence and the more 
cryptic PTS-2 [2, 29]. These targeting sequences are similar among kinetoplastids, yeast, 
and humans proteins translocated to glycosomes and peroxisomes. These observations 
      
 
Figure 1.4 Glycolysis in Trypanosoma brucei.  Glycolysis is partitioned into three organelles in the 
African trypanosome. The first seven steps occur in the glycosome. Hexokinase (HK), Phosphoglucose 
isomerase (PGI), Phosphofructokinase (PFK), Aldolase (ALD), Triose phosphate Isomerase (TPI), 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), Phosphoglycerate kinase (PGK), Glycerol-3-
phosphate dehydrogenase (GPDH), and Glycerol kinase (GK) are all found in the glycosome. 
Phosphoglycerate mutase (PGM), Enolase (ENO), and Pyruvate kinase (PK) are all found in the 
cytosol. The trypanosome alternative oxidase (GPO) is found in the mitochondria. These organelles 
must act in concert for ATP production and parasite adaptation. (Figure modified from [2].) 
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indicate that there is a similar evolutionary history among glycosomes and peroxisomes, 
but the appearance of glucose-related metabolism (glycolysis, gluconeogenesis, the 
pentose-phosphate pathway, and the Embden-Meyerhof pathway) and purine slavage 
pathways distinguish glycosomes as a unique organelle to the kinetoplastids. 
The glycosome houses the first seven reactions of glycolysis (Figure 1.4). This 
means there is no net ATP or NADH gain in the glycosome as glucose is oxidized to 3-
phosphoglycerate and glycerol-3-phosphate. Net ATP is generated in the cytoplasm by 
pyruvate kinase, which catalyzes the conversion of phosphoenol pyruvate to pyruvate. 
Pyruvate is then secreted from the parasite. Reducing equivalents (NAD+ and NADH) 
are maintained by a cooperative action of glyceraldehydes phosphate dehydrogenase, 
glycerophosphate dehydrogenase, and a mitochondrial glycerophosphate dehydrogenase 
(Reviewed in [15, 30, 31]).  
The limiting step of glycolysis in both life stages appears to be the availability of 
glucose and ATP [32]. While T.brucei possesses cellular glucose transporters, the 
transport mechanism of glucose into the glycosome remains unresolved. Similarly, the 
availability of ATP to initiate glycolysis by the actions of hexokinase and 
phophofructokinase is essential to glycolysis; given the relative impermeability of the 
membrane to small molecules such as ATP, the parasite must find methods to generate 
the initiating ATP. Perhaps this is provided by beta-oxidation of fatty acids [2]. Once the 
initial currency has been generated, the pathway will be able to maintain its own ATP 
supply and balance its reducing equivalents of NAD+ and NADH. 
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Given that other organisms carry out glycolysis in the cytosol, why is it so 
important for kinetoplastids to compartmentalize glycolysis in glycosomes? One theory 
suggests that the parasite does this to control cellular ATP [33] consumption by 
hexokinase and phosphofructokinase, which are not controlled by feedback inhibition 
[34]. The enzymes are sequestered preventing unchecked ATP depletion. In support of 
this, trypanosomes engineered to lack glycosomes grow normally in very low glucose 
media. However, addition of glucose is toxic to these cells, suggesting HK and PFK 
activity must be limited or sequestered in the presence of glucose to avoid toxicity [35]. 
Another possibility is that cytosolic function of mislocalized proteins may be detrimental 
to the cell. Evidence for this has been the overexpression of glycosomal 
phosphoglycerate kinase in the cytosol kills BSF T.brucei by either consuming substrates 
or generating toxic products [36]. Similarly, cytosolic expression of triose phosphate 
isomerase is also toxic to parasites probably as a result of interfering with the glycerol 
phosphate shunt [37]. Lastly, reducing equivalent pools for cytosol and glycosomes may 
be different. The ratio of NAD+/NADH in the glycosome may control the metabolic 
pathways within the glycosome; however, there exists no experimental support for this 
theory currently.   
Glycolysis in the African Trypanosome 
Of all the metabolic processes in T.brucei, glycolysis is the most well studied 
because it is the exclusive means of energy production in the BSF parasites. Glucose is 
rapidly degraded into pyruvate under aerobic conditions, which generates two ATP per 
glucose molecule. As mentioned above, the first seven steps of the pathway occur in the 
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glycosome with the final two ATP generating steps occurring in the cytosol [15, 30, 38] 
[31]. The enzymes of glycolysis in the BSF trypanosome make up roughly 3.3% of the 
total cellular protein; however, they are nearly 90% of the the glycosomal proteins [39]. 
All of the glycosomal glycolytic enzymes have a pI of between 8.8 and 10.2, which is 
substantially higher than values for glycolytic enzymes from other organisms [39]. Due 
to the localization of these enzymes to a specific organelle, isolation techniques have 
been designed to extract the organelles and their proteins for investigation. 
Glycolysis begins with the conversion of glucose to glucose-6-phosphate by 
hexokinase. T.brucei hexokinase (TbHK) activity was purified with a 300 MW complex 
that consisted of six 50 kDa monomeric subunits [39]. This subunit size coupled to the 
lack of feedback inhibition by glucose-6-phosphate and lack of nucleotide substrate 
specificity classifies TbHK as a nonvertebrate hexokinase [34]. When compared to 
vertebrate hexokinases, nonvertebrate hexokinases are smaller molecular weight 
hexokinases (50 to 60 kDa) opposed to 90-100 kDa that are not regulated by their 
products and lack specificity for nucleotides. The difference between TbHK and 
mammalian hexokinases has been the reason for its consideration as a drug target. 
Glucosephosphate isomerase catalyzes the conversion of glucose-6-phosphate to 
fructose-6-phosphate and is found as a dimer of 62 kDa proteins. Next, 
phosphofructokinase, which phosphorylates fructose-6-phosphate to make fructose-
1,6,bisphosphate, is found as a 200 MW tetramer of four 51 kDa monomers. T.brucei 
PFK acts as an allosteric protein with respect to fructose-6-phosphate while 5'-AMP acts 
as a positive effector; high concentrations of magnesium and ATP are inhibitory to 
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TbPFK [34]. Given that TbHK and TbPFK are unresponsive to modulators of glycolysis 
shown to increase or decrease glycolysis in other organisms, it is possible that they do not 
regulate glycolysis in T.brucei. 
The remaining four enzymes of aerobic glycolysis were found to be similar to 
those found in other eukaryotes. Aldolase, which breaks down fructose-1,6-bisphosphate 
into triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-
phosphate (GA3P), is a tetramer comprised of 41 kDa monomers[39]. Triose phosphate 
isomerase (TIM) is a dimer of 27 kDa subunits[39]. TIM catalyzes the isomerization of 
DHAP to GA3P. Glyceraldehyde-3-phosphate dehydrogenase (GA3PDH) converts 
GA3P to 1,3 bisphosphoglycerate (1,3-BPG) while reducing NAD+ to NADH. This 
enzyme is a tetramer of 39 kDa subunits [39]. Lastly, phosphosglycerate kinase is a 47 
kDa monomer [39] that catalyzes the dephosphorylation of 1,3-BPG to 3-
phosphoglycerate, subsequently ADP is phosphorylated to make ATP. 
3-phosphoglycerate is shuttled into the cytosol, and phosphoglycerate mutase 
converts it to 2-phophoglycerate, which is dehydrated by enolase to make 
phosphoenolpyruvate (PEP). In BSF parasites grown under aerobic conditions, PEP is 
reacts with ADP to make pyruvate and ATP. Pyruvate is then secreted into the host by 
the parasite. Lactate dehydrogenase activity is not found in the parasite, thus aerobic 
glycolysis ends with pyruvate. 
Studies have also been performed on the role of anaerobic glycolysis in the 
African trypanosome. Under anaerobic conditions, glucose is oxidized into equimolar 
amounts of pyruvate and glycerol [40]. The pathway to pyruvate is the same as 
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mentioned earlier; however, in the glycosome, DHAP is reduced to glycerol-3-phosphate 
by NADH-dependent glycerol-3-phosphate dehydrogenase [40]. Glycerol-3-phosphate is 
subsequently dephosphorylated to glycerol by glycerol kinase and ATP is produced. 
However, recent work involving glycerol kinase would suggest that the aforementioned 
reaction do not occur in trypanosomes. The conversion of glycerol-3-phosphate to 
glycerol proceeded at a very slow rate, and had an unfavorable ∆G, thus glycerol is most 
likely used to help maintain reducing equivalents in the glycosome [41]  Glycerol-3-
phosphate dehydrogenase exists as a dimer of 37 kDa subunits, with glycerol kinase as 
dimer of 53 kDa subunits [39]. 
Glycolytic kinases (hexokinase, phosphofructokinase, and pyruvate kinase), that 
are regulated in other systems to temper glycolysis, do not appear to exert any control 
over glycolysis in the BSF trypanosome. Glycolysis is likely controlled by glucose 
uptake and the ability of the cell to translocate the glucose into the glycosome [42]. This 
was shown using metabolic control analysis, respiration measurements, and ATP 
production and consumption in culture and in rats [42]. The glucose transporter 
relinquished flux control at 10 mM glucose, and control is passed to other glycosomal 
enzymes, aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase 
and glycerol-3-phosphate dehydrogenase [42]. Although the flux control values ascribed 
these enzymes are relatively low (16%, 14%, 9%, and 10%, repectively), ATP production 
and metabolic control analysis indicate they could have regulatory capacity when glucose 
transporters no longer have control of glucose flux. In addition ATP utilization by the 
glycolytic components of the glycosome exerts little control as well. By discerning 
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ATP/AMP ratios and utilizing metabolic control analysis, it was determined that 
glycosomal ATP could not regulate metabolism as there was no net production by 
glycolysis[42]. This unique form of regulation is another difference between glycolysis in 
T.brucei and other eukaryotes. 
Hexokinases 
Hexokinases (EC 2.7.1.1: ATP:D-Glucose-6-phosphotransferase) (HKs) are the 
family of enzymes responsible for initiating hexose metabolism in cells. HKs catalyze the 
transfer of the γ-phosphoyl group of ATP to the C-6 of glucose.  
Hexokinases can be classified into four different isozymes (I, II, III, IV) based on 
electrophoretic mobility of proteins found in mammals [43]. All isozymes are not found 
in all organisms due to their differences in substrate specificity and regulation. 
Consequently, organisms containing all four isozymes (vertebrates) will often express the 
enzymes in separate tissues. Type I-III hexokinases are considered high affinity 
hexokinases, while Type IV hexokinases (also known as glucokinases)  have KMs above 
5 mM; additionally, glucokinases differ from the other three isozymes in regulation [43]. 
Types I-III are inhibited completely by glucose-6-phosphate and glucokinases are not 
inhibited by glucose-6-phosphate [44]. The high affinity hexokinases differ in regulation 
also. Type I hexokinases can use low concentrations of phosphate to overcome glucose-
6-phosphate inhibition, while high concentrations of phosphate inhibit the isozyme [44]. 
Type II hexokinases are always inhibited by phosphate [44]. Type III hexokinases, the 
least studied of the isozymes, is inhibited by high concentrations of glucose and is 
inhibited by phosphate [44]. These four isozymes in vertebrates provide for enzymatic 
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specificity in the tissues and subcellular regions they are found [44]. While the primary 
sequences of hexokinases may change from organism to organism, there are crucial 
motifs that do not change. Some of these highly conserved motifs are found in Figure 1.5. 
Mammalian (vertebrate) hexokinases 
 As mentioned above, vertebrates are the only organisms to possess all four 
hexokinase isozymes. The most well studied vertebrate (with respect to hexokinases) has 
been the rat, so most of the available data on the isozymes will come from studies in this 
organism. Type I-III hexokinases are found in the throughout the mammal (brain, muscle, 
etc.), while the Type IV hexokinase resides in the liver and pancreas [44]. Vertebrate 
hexokinases I-III are among the largest hexokinases. Molecular weights of these 
hexokinases are approximately 100 kDa; this is twice the size of the Type IV hexokinase 
(50 kDa) [43].  
Plant hexokinases 
 Plants have at least three isozymes of hexokinase that provide the organisms with 
the enzymatic diversity to drive metabolism {Claeyssen, E. Phytochemistry. 68. 2007. 
709}. However, there does not appear to be a specialized glucokinase as found in 
vertebrates. Plant HKs can utilize the by products of sucrose and starch degradation along 
with other metabolic pathways to drive energy metabolism and synthesize complex 
carbohydrates [45]. A unique aspect of plant hexokinase isoforms is that they may be 
separated by subcellular localization [45]. It appears that the dominant plant hexokinase 
isoform is localized to the mitochondria, while another isoform is localized to the plastids 
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[45].This suggests that different methods of regulation for cytosolic and plastid glycolysis 
 
could exist [45]. Similar to vertebrates, plants can also have hexokinases range in size 
from ~50 kDa to ~100 kDa [43]. 
 























































Figure 1.5 Motifs in hexokinases can be highly conserved. Hexokinase sequences from selected 
eukaryotes were aligned using ClustalWX. The sequences included are: human hexokinase 
(HXK1_HUMAN, P19367), Arabidopsis thaliana HXK1 (HXK1_ARATH, Q42525), Saccharomyces 
cerevisiae HXK1 (HXK1_YEAST, P04806), Schistosoma mansoni HXK1 (HXK1_SCHMA, Q26609), 
Leishmania major HXK1 (HXK1_LEIMA, XP_001682957), T.cruzi HXK1 (HXK1_TRYCR, 
XP_808992), TbHK1 (HK1_TRYBR, CAC69958) and TbHK2 (HK2_TRYBR, EAN77629). Motifs 
are identified by their amino acids, where x represents any amino acid and h represents hydrophobic 
amino acids. The functions of these motifs are noted as Loop (participating in a loop region), ATP 
(involved in ATP binding), Phosphotransfer (responsible for transferring phosphoryl group to hexoase), 
and hexose (involved in hexose binding). All residues are conserved with the exception of 
HK2_TRYBR, which has a G in place of the D in the DGSGhGAA motif. 
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Yeast hexokinases 
 Similar to plants, Saccharomyces cerevisiae has three hexokinase isoforms; 
however, yeast have a glucokinase [43].  S.cerevisiae also has a Type I and Type II 
hexokinase [46]. The  
functions of these are nearly the same as mentioned above; however, the Type I and Type 
II can form dimers [43]. The permits the Type II hexokinase to exert allosteric control 
over the Type I. A unique aspect of the yeast Type II hexokinase is that it can translocate 
to the nucleus to regulate gene expression in response to environmental conditions [47].    
Other hexokinases 
 Bacteria possess the smallest hexokinases; they have molecular weights of 
approximately 25 kDa [43]. The bacterial hexokinases are highly specific for their 
substrate, having one enzyme per hexose [43]. In eukaryotes, the size of the enzymes 
increases to ~50 kDa, and the enzymes can use multiple substrates [43]. Hexokinases 
have been characterized in many ‘lower eukaryotes’ and small variations in the primary 
sequences of these polypeptides have been shown to impact substrate specificity and 
regulation greatly. Some of the most well studied primitive eukaryote hexokinases have 
been in parasitic eukaryotes. Entamoeba histolytica [48], Schistosoma mansoni [49], 
Toxoplasma gondii [50], Plasmodium falciparum  [51], Leishmania major [52], 
Trypanosoma cruzi [53], and Giardia lamdia [54] hexokinases have all been 




Hexokinase Catalysis and Structure 
The catalysis of hexokinases has also been studied extensively. The mechanism of 
this phosphotransfer is one of the most well-studied in all of science. In this reaction, the 
enzyme forms a ternary complex with Mg2+-ATP and glucose. The Mg2+ ion interacts 
with oxygens on the beta and gamma phosphates to shield the negative charge associated 
with them. This permits the oxygen of the C-6 hydroxyl group to nucleophilically attack 
the γ-phosphate of ATP when in close proximity [55].  
Despite the simplicity of mechanism, there is a thermodynamic problem with the 
transfer of a phosphate to a hexose in an aqueous environment. The hydrolysis of ATP to 
ADP and Pi is favored in water, and it would occur ~40,000 times faster than a transfer to 
a hexose [55]. The solution was revealed when an X-ray structure of S. cerevisiae 
hexokinase (ScHXK) in the presence and absence of substrates were acquired. ScHXK 
was found to be a two lobed enzyme and in the absence of substrate the two lobes were 
separated by a large hydrophobic groove [46] (Figure 1.6). Upon binding glucose near 
the hydrophobic groove, it was found that the lobes moved together, a change of nearly 8 
Å. This closed conformation induced by glucose is sufficient to bring the hexose into 
proximity with Mg-ATP complex, and the area surrounding the substrates and amino 
acids in the hydrophobic is so compact water is omitted and restricted from entering the 
active site. Consequently, the environment created in the close form of ScHXK favors the 
transfer of the γ-phosphate from ATP to the hexose by the aforementioned mechanism 
[46, 55] 
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This deep hydrophobic cleft is a common feature to all sugar kinases (phosphate 
transferases) and it is also found in heat shock proteins (Hsp), cell cycle proteins, and 
actin [56] (Figure 1.6). This motif, the actin fold, is important to all ATPase domains in 
proteins. The actin fold is the region responsible for binding ATP and closing the two 
halves of the fold which results in the altered structure of the protein. The actin fold of 
ATPase domains consists of five conserved motifs: The PHOSPHATE1, PHOSPHATE2, 
ADENOSINE, CONNECT1, and CONNECT2. The ADENOSINE motif is found near 
the bottom the hydrophobic groove of the fold and is responsible for binding the 
adenosine of ATP [56]. The PHOSPHATE1 and PHOSPHATE2 motifs are required for 
complete binding of the phosphate side chain of ATP. The CONNECT1  and 
CONNECT2 helices are two motifs running antiparallel and are responsible for closing 
the groove and bringing the lobes flanking the grooves together[56]. This is achieved 
when the two regions make a helix-helix interaction between an invariant glycine on 
CONNECT2 and a glutamic acid and alanine on CONNECT1[56]. This interactions 
serves as a hinge to promote molecular movement. The actin fold permits the exclusion 
of water to favor phosphoryl transfer to the hexose. 
Since the first hexokinase structure was elucidated from yeast hexokinase, the 
mechanisms and structural conformations associated with most hexokinases have been 
derived from ScHXK data; therefore, ScHXK studies can be used to introduce the many 
biochemical events that occur during catalysis. The highest resolution for a hexokinase 
was obtained from ScHXK PII in 2000 by Kuser, et al.[46]. The sequence of ScHXK PII 
was compared to other eukaryotic hexokinases, and it was determined that the enzymes 
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shared 34% identity[46]. It was clear that the enzymes have the conserved kinase 
structure of two lobes, one small and one large, separated by a hydrophobic groove (actin 
fold). The enzymes had high levels of conserved residue required for catalysis; 
surprisingly, many glycines were highly conserved indicating that the enzymes have a 
flexible structure that is necessary to bind their substrates [46]. Additional studies were 
performed in the presence/absence of ortho-toluoylglucosamine (OTGn), a competitive 
inhibitor of hexokinases, in order to simulate substrate binding. With respect to the large 
lobe, four loops (L1-4) were found to move up to 8Å in the presence of glucose, and 
mutagenesis reveals that these loops are also necessary for nucleotide binding. L1(87 
LGGTN91) and L4(174WTKGF178) are highly conserved among all but two 
hexokinases used in the study[46]. Changes in the L1 or L4 sequences resulted in a lack 
of catalytic activity as found in human and rat hexokinases when L1 residues Thr90 and 
Asn91 were substituted with serines or on L4 when  Gly177 was changed to an arginine 
[46]. 
In addition to the loop recognition, the binding site for glucose was further 
resolved; while Asp211 was labeled as the residue responsible for facilitating the 
nucleophillic attack on the γ-phosphate of ATP by C-6, Asn237, Glu269, and Glu302 
were also found to hydrogen bond to OTGn at O-4, O-3, and O-1, respectively [46]. 
Simultaneously, cleft closure brings small lobe residues Thr172 and Lys173 into 
proximity with glucose for bonding [46]. Ser158 in the closed conformation interacted 
with the C-3 hydroxyl of glucose, and mutagenesis of this residue to an alanine resulted 
in an inactive enzyme [57]. 
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Using 8-bromo-AMP, the ATP binding site was also investigated during the 
ScHXK study. While modeling indicated that residues 344-348 and 422-424 played a 
role in adenine ring binding, all motifs of the actin fold were found to be involved  
(PHOSPHATE1 (82-103), PHOSPHATE2 (229-248), ADENOSINE (411-439), 
CONNECT1(203-223), and CONNECT2 (453-473)) [56] [46]. It was also noted that 
several Gly, Ser, Thr, and Asp residues in the actin fold motifs were conserved among the 
 
hexokinases in the study. Based on the binding of a sulfate ion to the ScHXK structure, 
Thr234 of PHOSPHATE2 and Ser419 of ADENOSINE were implicated in phosphate 
and monophosphate binding further expanding the roles for these motifs [46].   
In addition to the further characterizing recognized domains in HKs, this study 
has described a conserved hydrophobic channel responsible for carrying protons from the 
    
Figure 1.6 Schematic of S.cerevisiae Hexokinase PII.  ScHXK was modeled based on crystal 
structure. Here the large and small lobes, the hydrophobic cleft, and loop regions of the large lobe are 
highlighted. The hinge region in the hydrophobic cleft is home to most active site residues and is made 
from an actin fold domain. 
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active site to maintain a favorable charge for catalysis in the active site. The residues I85, 
L87, L127, I131, L135, M139, L153, F155, F157, F178, L192, and I196 were identified 
as residues responsible for this function, creating a structure that was ~3Å 
 wide and 25Å long [46]. 
Understanding how these molecules are bound in the enzyme can help us to 
understand how single residue changes within or near the active can alter the enzyme’s 
specificity and catalytic nature. Several studies have been done on yeast and mammalian 
HKs to identify residues that may inhibit or enhance HK catalysis. In a mammalian 
mutagenic and crystallographic study of hexokinase, residues in the C-terminus (Asp532, 
Arg539, Gly897 and Gly898) were shown to be necessary for catalysis and speculated to 
be involved in ATP-binding. In the same study, C158 and C606 were found to be 
required for inhibition by Glc-6-P and Pi, and were the hallmark residues of mammalian 
Type I hexokinases [58]. While other mutagenesis studies have helped to identify the 
homologous catalytic residues mentioned above, one particular study on yeast hexokinase 
sought to identify residues away from the active site that were detrimental to HK activity. 
Five residues, Gly89, Ser306, Thr90, Gln376, Ile238, were not within hydrogen bonding 
distance to any site associated with catalysis [59]. This would suggest that the entire 
structure of hexokinases are critical to the mechanism of catalysis and are specific to 
individual hexokinases.  
Regulation of Hexokinases 
While hexokinases have some interesting catalytic and structural biochemistry, 
the regulation of these molecules is equally as interesting. Hexokinases have been known 
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to be regulated by their own products, other metabolites or post-translational 
modifications. All of these mechanism of regulation can impact catalysis and protein 
function.  
The most common form of regulation of hexokinase catalysis is feedback 
inhibition by its product Glc-6-P. Not all enzymes are inhibited in this manner, with 
human glucokinase (Type IV HK), Type II mammalian HKs, and several protozoan and 
bacterial HKs being notable exceptions. Glucose-6-phosphate inhibits HKs by binding in 
the active site and acting as a competitive inhibitor, or it can bind to an alternate site on 
the enzyme and regulate it allosterically.  
The influence of divalent metal ions on catalytic activity is varied; however, it 
appears that many divalent ions can act in place of Mg2+, but given that Mg2+ is the most 
abundant physiological divalent ion, it is generally involved in the reaction. ADP, the 
other product of hexokinase, that can act as an activator of hexokinase in conjunction 
with the other nucleotide AMP in certain hexokinases. ADP can bind to an allosteric site 
on the enzyme promoting ATP binding [60] .  
Aside from its own products, hexokinase can also be regulated by other 
intermediary metabolites produce by glycolysis and gluconeogenesis.  Fructose-6-
phosphate has been shown to indirectly inhibit several hexokinases [61, 62]. Fructose-
1,6-bisphosphate has been shown to activate some HKs. Fructose-2,6-bisphosphate can 
also negatively impact some hexokinases [63]. In addition to these metabolites, 
pyrophosphate and orthophosphate can impact HK activities positively or negatively 
 27 
depending on the hexokinase. Similarly tricarboxylic acid cycle metabolites, namely 3-
phosphoglycerate, citrate and malate, can activate hexokinases [64, 65] 
Other metabolites known to inhibit hexokinase include fatty acids and fatty acyl-
CoAs [66, 67]. Fatty acyl-CoA inhibition is common, and is best typified by a study 
shown with rat liver glucokinase [67]. Here fatty acyl-CoAs inhibited the enzyme at sub-
critical micelle concentrations suggesting that the molecule bound directly to the enzyme 
and was not related to detergent effects [66]. Free fatty acid inhibition, for example, is 
found in skeletal muscle hexokinase [66]; however no direct associations between the 
enzyme and fatty acid have been shown. 
Small metabolites are potent inhibitors of hexokinases, and each hexokinase has a 
primary sequence that dictates the molecules that it can bind, subsequently the same is 
true for post-translational modifications of the enzyme.  Autophosphorylation of 
hexokinases have been demonstrated in the presence of xylose, a hexose that lacks a C6 
hydroxyl [68]. Hence, the enzyme, with out a hydroxyl on the sugar to transfer the 
phosphate to attached it to the nearest hydroxyl group on the enzyme. Another 
phosphorylation may occur via AMP-dependent kinase [69]. In situations where ATP is 
being depleted in the cell, AMPk  phosphorylation can modulate HK activity in order to 
control the amount of ATP being consumed. Lastly, HKs have the ability to oligomerize, 
often as dimers. In yeast, assortments of oligomers can be assembled to modulate the 




Alternative Hexokinase Functions 
The catalysis, structure and regulation of HKs is fascinating; additionally, these 
molecules can have alternative functions. In S.cerevisiae, a hexokinase is responsible for 
the modulation of gene expression required to adapt the organism to different carbon 
sources [71]. Hexokinase-2 (HXK2) of S.cerevisiae is localized in both the nucleus and 
cytoplasm, and the enzyme in the nucleus is capable of regulating gene expression, 
including its own. Under high glucose conditions, the enzyme interacts with Med8 and 
Mig1 at the Hxk2 promoter. This action prevents transcription through the gene by RNA 
Polymerase II. In low glucose environments, the enzyme is localized in the cytoplasm, 
and does not interfere with gene transcription (Reviewed in [72], [47]). A similar 
phenomenon has been noted in plant. Arabidopsis thaliana hexokinase-1 (AtHXK1) has 
been demonstrated to be a sugar sensor and a component of pathways involved in 
hormone, nutrient, and light responses [73, 74] Generation of an A.thaliana glucose 
insensitive mutant revealed AtHXK1 lacked catalytic activity, but could still respond to 
environmental stimuli to control cell proliferation, leaf expression, root and 
influorescence growth, and gene expression. This study demonstrated that the glucose 
signaling was independent of HK catalytic activity in A.thaliana[74]. Similar signaling 
events have been found in mammals and E.coli, demonstrating that hexokinases are not 
only important metabolically, but also represent a widespread sensor family [75, 76] [77]. 
Trypanosoma brucei HKs 
 Trypanosoma brucei hexokinase (TbHK) activity was first isolated from 
glycosomes from BSF parasites. The activity was isolated as a hexameric 300 MW 
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complex made up of 50 kDa constituents [39]. The authentic enzyme had high affinity for 
glucose of (KM = 17 µM) and ATP (KM = 116 µM) had a broad pH range (pH 6 to pH8.5) 
for hexokinase activity, and lacked nucleotide specificity. The enzyme was able to utilize 
ATP, ITP, CTP, GTP, and UTP to phosphorylate hexoses. Additionally, the enzyme was 
not controlled allosterically or competitively by its product glucose-6-phosphate [34]. 
 Upon completion of the T.brucei genome, it was revealed that the parasite had 
two hexokinase genes, TbHK1 and TbHK2. These genes are located in tandem on 
chromosome 10, and produce polypeptides that are 98% identical at the amino acid level 
[18]. Both genes are transcribed [18]. Additionally, proteomic analysis of glycosomes has 
revealed that both proteins are expressed in both life stages of the organism [21]. 
 Due to the similarities of the two proteins and the difficulties of trying to identify 
the protein responsible for activity in protein complexes, recombinat proteins of both 
TbHK1 and TbHK2 were expressed and purified from E.coli. Recombinant TbHK1 
exhibited similar catalytic behavior to other hexokinases. TbHK1 had KMs for glucose 
and ATP of 0.09 µM and 0.28 µM, respectively. TbHK2 lacked any discernable 
hexokinase catalytic activity [4]. In addition to glucose, TbHK1 was able to use fructose, 
mannose, 2-deoxyglucose, and glucosoamine as substrates. TbHK1 demonstrated 
nucleotide specificity as it was able to use ATP and UTP but not  GTP, CTP and ITP. 
TbHK1 prefers Mg2+ as its divalent cation (KM = 0.92 mM), and Ca
2+ was inhibitory [4]. 
TbHK1 was not inhibited by Glc-6-P or ADP, but was inhibited by medium to long 
length fatty acids. The most potent fatty acid inhibitors of rTbHK1 were myristic acid 
and palmitic acid having IC50s of 78 and 63 µM, respectively [4]. 
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 Primary sequence comparisons of TbHK1 to other hexokinases using the ConSurf 
alignment program revealed that the protein had 33% identitiy to ScHXK and most of the 
conserved residues were present [4]. To determine if the catalysis of TbHK1 required 
conserved residues, S160 and G93, which are involved in ATP binding and phosphoryl 
transfer, were mutated. Each mutation resulted in a lack of hexokinase activity suggesting 
that TbHK1 had an enzymatic mechanism similar to other hexokinases [4].  
 Seven of the ten amino acid differences between TbHK1 and TbHK2 were found 
at the C-terminus of the polypeptides [4]. To examine the impact of this region, the C-
termini of TbHK1 was replaced by the C-termini of TbHK2. This exchange resulted in 
the loss of catalytic activity in TbHK1 with the TbHK2 tail. However, exchanging the C-
terminus of TbHK2 with that of TbHK1 resulted in an active enzyme that was identical to 
wild type (Figure 1.7) [4]. This result indicates that the C-termini of the two polypeptides 
regulate the enzymatic activity of the two proteins. 
 Homozygous null knockouts were attempted to ascertain possible functions of the 
two proteins. Knockouts of TbHK1 in BSF or PF parasites were not successful, while 
heterozygous null TbHK1 knockouts in PF parasites exhibited a severe growth phenotype 
(Morris, M, unpublished data). This suggests that the gene is essential to the parasite. 
TbHK2 knockout cells were made in PF trypanosomes, yielding cells with a distinct 
phenotype. These cells were elongated compared to wild type and demonstrated a 5-fold 
increase in hexokinase activity, an increase was a result of in the increase in TbHK1 
polypeptide in these cells [4]. These results indicated that TbHK2 may regulate TbHK1 




       
 
Figure 1.7 TheC-terminal tails of T.brucei hexokinases regulate activity.  (A) Recombinant TbHKs 
were produced in E.coli and assayed for hexokinase activity. Hexokinase 1 (ThHK1) and TbHK2 with 
the C-terminal tail of TbHK1 (TbHK2C1) demonstrated similar hexokinase activity, while Hexokinase 
2  (TbHK2) and  TbHK1 with the C-terminal tail of TbHK2 (TbHK1C2) lacked detectable activity. (B) 
Proteins were analyzed by SDS-PAGE followed by Coomassie staining [4].  
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Abstract 
Trypanosoma brucei harbors two hexokinases (TbHK1 and TbHK2) that are 98% 
identical at the amino acid level.  We previously found that recombinant TbHK1 
(rTbHK1) has hexokinase activity, while rTbHK2 does not, a finding attributed to 
differences in the C-termini of the proteins.  Sequence analysis suggests that the C-
termini of TbHKs are part of a newly identified conserved motif found in other 
eukaryotic hexokinases.  Here, we have explored the role of tail residues in the 
differences in catalytic activity between TbHK1 and TbHK2.  Our studies reveal that tail 
residues D454, F462, M466, and N469 are essential for HK activity while both I458 and 
V468 are required for catalysis and substrate specificity.  To activate rTbHK2, all of the 
residues important for activity in rTbHK1 (D454, V458, F462, M466, V468, and N469) 
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were required.  These results indicate that the overall structure of the C-terminal tail 
influences the HK activity of rTbHK1. 
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Introduction 
The infectious agent responsible for African sleeping sickness, Trypanosoma brucei, 
metabolizes glucose by glycolysis to generate ATP as its sole source of energy in its 
mammalian host.  In the first step of glucose catabolism, hexokinase (HK) catalyzes the 
transfer of the γ-phosphoryl group of ATP to glucose to yield glucose-6-phosphate and 
ADP.  T. brucei HK isolated from parasites revealed that the enzyme has several unusual 
properties.  First, unlike many eukaryotic HKs, the enzyme is not inhibited by its product 
[1, 2].  Additionally, while most other characterized HKs exist as monomers or dimers, T. 
brucei HK forms oligomers consisting of six subunits [2].  Last, the enzyme is localized 
in an unusual organelle, the glycosome, which houses glycolytic enzymes. 
While the consequences of oligomerization are currently unresolved, the recent 
revelation that the T. brucei genome harbors two tandemly arranged HK genes on 
chromosome 10 [3] complicates the potential make-up of the hexamers.  The HK genes 
yield 98% identical polypeptides (TbHK1 and TbHK2) that have been found in 
glycosomes in both insect stage parasites (also called procyclic forms, PF) and blood 
stream form (BSF) parasites [4].  
Producing both HKs recombinantly in E. coli, we found that rTbHK1 was a 
catalytically active HK, whereas rTbHK2 lacked detectable HK activity [5].  Seven of the 
ten amino acid differences between TbHK1 and TbHK2 are in the terminal eighteen 
amino acids of the two proteins.  Exchanging the C-termini of rTbHK1 with that of 
rTbHK2, activated rTbHK2, while rTbHK1 with the tail of rTbHK2 was inactivated [5]. 
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Because HKs function in the first step of glycolysis, an essential pathway in the 
infective stage of the life cycle [6], understanding the enzymology of these proteins is 
crucial to understanding energy metabolism in T. brucei.  We have employed site-
directed mutagenesis and molecular modeling to explore how the C-terminal tail of 
TbHK1 influences catalysis and to determine why TbHK2 may not have HK activity. 
These studies shed new insight into the mechanism of T. brucei HKs. 
 
Materials and Methods 
Expression and purification of mutant recombinant TbHK1 and TbHK2 
Recombinant TbHKs, rTbHK1 and rTbHK2, were expressed and purified as 
previously described [5].  Site-directed mutagenesis to generate changes in the carboxy 
tails of rTbHK1 and TbHK2 was performed using a PCR based procedure.  
Oligonucleotide primers were designed containing the changes required to introduce the 
mutations flanked by codons for the unaltered residues of the C-terminus (Table A.1).  
Each oligonucleotide primer was modified to contain a restriction enzyme site following 
the stop codon to permit rapid identification of mutant DNA by restriction digest.  Mutant 
open reading frames were amplified by PCR using the 3’ mutagenic primers along with a 
common forward primer for TbHKs (5’-GATC 
GGATCCTCTAGACGCCTAAACAATATCC-3’). PCR products were cloned into 
pQE30 (Qiagen, Inc., Valencia, CA), transformed into M15(pREP) E. coli, expressed, 
and purified as described in [5].  
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TbHK1:S456A, TbHK2:S456A, and TbHK2:G454D were generated by site 
directed mutagenesis using the Finnzymes Phusion Site-Directed Mutagenesis Kit (New 
England Biolabs, Inc., Ipswich, MA) (Table A.2). The TbHK2:4Tail mutant (TbHK2: 
G454D, L462F, I466M, and D469N) was made using the TbHK2:3HelixMUT(TbHK2: 
L462F, I466M, and D469N) primer in a PCR reaction using a template containing the 
TbHK2:G454D mutation. TbHK2:5TailMUT (TbHK2:D454G, L462F, I466M, D469N, 
and G470D) was generated by using the R.TbHK2:G470DD469N primer on 
pQE30:TbHK2:4TailMUT plasmid template.  Mutations were confirmed by sequencing 
the PCR products cloned and transformed into M15:pREP4 cells. 
Modeling and assaying recombinant TbHKs 
 TbHK1, TbHK1(N469D), and TbHK2 were modeled on both the Saccharomyces 
cerevisiae HK structure (PDB ID: 1IG8, GI:1150586) and the Schistosoma mansoni HK 
structure (PDB ID: 1BDG; GI:5107491) using DS Modeler (Accelrys) with the standard 
parameters built into the program.  The structures were viewed using DS Visualizer 
(Accelrys).  Structures were aligned by sequence and then centered on catalytic residue 
D214.  
HK assays were performed in triplicate on at least two independent protein 
preparations as described [5].  Briefly, HK generated glucose-6-phophate was oxidized to 
6-phosphogluconate using glucose-6-phosphate dehydrogenase.  The concomitant 
reduction of NAD+ to NADH was monitored spectrophotometrically at 340 nm.  
Alternatively, a coupled reaction using pyruvate kinase and lactate dehydrogenase was 
employed to monitor HK activity with substrates other than glucose.  In the presence of 
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PEP, pyruvate kinase utilizes ADP produced by the HK reaction to regenerate ATP.  The 
pyruvate that is produced as a result of this reaction is then converted to lactate by lacate 
dehyrogenase, which oxidizes NADH to NAD+, a process that is monitored at 340 nm.   
Kinetic analyses were performed using KaleidaGraph 4.1 (Synergy Software, Reading, 
PA) with the Michaelis-Menton curve fit algorithm.  
Results 
The C-terminal tails of TbHK1 and TbHK2 are part of the CONNECT2 domain of actin 
fold proteins.   
TbHK1 and TbHK2 share a conserved structural motif, the actin fold, with actin, 
sugar kinases, and hsp70 [7].  This motif, which is involved in ATP binding, consists of 
five domains, including the PHOSPHATE1, CONNECT1, PHOSPHATE2, 
ADENOSINE, and CONNECT2 domains [8].  The C-termini of TbHK1 and TbHK2 are 
conserved components of the CONNECT2 domain, a portion of the polypeptide that, 
along with the CONNECT1 domain, is predicted to connect the two lobes of HKs 
through close helix:helix interactions in the hinge region of the protein to promote 
closing of the enzyme when substrate is bound [8]. Crystal studies of human, yeast, and 
Schistosoma mansoni HKs support the positioning of these sequences in a hydrophobic 
groove proximal to the active site [9-11]. 
The CONNECT2 domain is characterized by a conserved Gly surrounded by 
hydrophobic and small polar residues, with the consensus sequence pxxtthhGhhhxhxh 
(where p is small polar residues, x is any residue, t is small amino acids, and h is 
hydrophobic residues) [8].  The CONNECT2 domain is completely conserved in both 
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TbHK1 and 2, being centered on G457 in the polypeptides.  G457 likely forms a key 
contact with CONNECT1, particularly with S221, a conserved residue within the 
CONNECT1 (numbered according to its position in TbHK1 and TbHK2) [8].  
Alignment of TbHK1 and TbHK2 C-terminal domains with eukaryotic HKs reveals a new 
motif.  
 Alignment of TbHK1 and TbHK2 C-termini with the CONNECT2 domains of 
other eukaryotic HKs suggests the presence of a conserved HK-specific motif in the final 
α-helix of eukaryotic HKs (HXKα13HELIX, pDGSGhGAA, Figure 2.1A).  The first 
residue in the motif is a small polar amino acid (p) followed by DGSG.  A hydrophobic 
amino acid (h) is then followed by GAA.  While this motif is found in HKs from 
mammals to protozoa (Figure 2.1A), there are a few exceptions.  For example, the HKs 
from Entamoeba spp. have a Val substituted for the second Ala in the motif.  
Interestingly, rTbHK2, which lacks detectable HK activity, harbors a Gly instead of the 
conserved Asp (Figure 2.1A).  Mutation of rTbHK1 within this domain (at residues D454 
or S456) inactivates the enzyme (see below), confirming the importance of these residues 
for catalysis. 
The C-terminal tails of TbHK1 and TbHK2 are on α-helix 13, proximal to the enzyme 
active site.   
When T. brucei HKs were modeled to S.cerevisiae PII HK, both trypanosome 











hydrophobic groove (Figure 2.1B).  Further, residues required for substrate binding and  
catalysis (glucose and ATP binding) were found in similar positions in the models.  The  
C-terminal tails, the region of highest divergence between TbHK1 and TbHK2, reside on 
the final α-helix (α-13) of the polypeptides (Figure 2.1B).  The N-terminal portion of α-
13 is proximal to the active site in the hydrophobic cleft of the enzymes (Figure 2.1B), 
suggesting that this helix may impact the positioning of active site residues, including the 
conserved catalytic residue D214.  To investigate the impact of amino acid differences 
Figure 2.1 The C-termini of TbHK1 and 2 share conserved features and similar positioning in 
enzyme models.  (A.) Alignment of C-terminal domains of HKs reveals conserved motif from the 
CONNECT2 helix of ATPase domains. Sequences were aligned ClustalWX.  These sequences include:  
human HXK1 (HXK1_Human, P19367), murine HXK1 (HXK1_MOUSE, P17710), Xenopus laevis 
HK (HK1A_XENP, AAH72832), Arabidopsis thaliana HXK1 (HXK1_ARATH, Q42525), Oryza 
sativa HXK1 (HXK1_ORYZA, AAV59322), Drosophila melanogaster HXK1 (HXK1_DROME, 
Q9NFT9), Saccharomyces cerevisiae HXK1 (HXKA_YEAST, P04806), S.cerevisiae HXK2 
(HXKB_YEAST, P04807), Schizosaccharomyces pombe HXK1 (HXK1_SCHIPO, CAA63487), 
Schistosoma mansoni HXK (HXK_SCHMA, Q26609), Toxoplasma gondii HXK (HXK_TOXGO, 
Q969A8), Leishmania major HXK1 (HXK1_LEIMA, XP_001682957), L. major HXK2 
(HXK2_LEIMA, XP_001682958), T. cruzi HXK1 (HXK1_TRYCR, XP_808992), T.cruzi HXK2 
(HXK2_TRYCR, XP_816463), TbHK1 (HK1_TRYBR, CAC69958), and TbHK2 (HK2_TRYBR, 
EAN77629). Residues mutated in this study are indicated by an (*).  The HXKα13HELIX and 
CONNECT2 motifs are included.  (B.) TbHK1 was modeled to S.cerevisiae hexokinase PII.  C-terminal 
domains (boxed) are found between the small and large lobes near the active site residue, D214.  A 
model of the TbHK1 C-terminal tail is included, with residues essential for activity are indicated. 
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between TbHK1 and TbHK2 on catalysis, site-directed mutagenesis was performed on 
rTbHK1, with single residue changes to the respective amino acids in TbHK2 made first. 
Changes within the C-terminal tails have profound effect on enzyme activity.   
TbHK1 residues were altered to the corresponding amino acids in TbHK2, and 
purified recombinant variant proteins were assayed for HK activity.  Three enzyme 
variants (I458V, V468A, and D470G) had apparent Km values for glucose that were 
similar to wild-type TbHK1.  The variants had values 1.2-fold lower, 1.5-fold higher, and 
1.5-fold lower, respectively, than the wild-type TbHK1 apparent Km (0.6 +/- 0.04 mM) 
(Figure 2.2A, Table 2.1 [5]).  
We also investigated the relative affinities of the enzymes for ATP and Mg2+.  
TbHK1:I458V had apparent Km values 4.1 and 1.6-fold lower for ATP and Mg
2+, 
respectively, than wild-type enzyme.  TbHK1:V468A  had apparent Km values for ATP 
and Mg2+ 3.6 and 2.45-fold lower than TbHK1, while TbHK1:D470G had apparent Km 
values 1.12 and 4.9-fold lower for ATP and Mg2+, respectively.   
To explore the impact of the C-terminal tail mutations on substrate specificity, we 
tested I458V, V468A, and D470G enzyme variants in assays using mannose and fructose 
as substrates. The variants exhibited near wild type apparent Km values for mannose with 
the three enzymes having values within a factor of three of wild-type enzyme (Table 2.1).  
The apparent Km values for fructose of TbHK1:I458V (3.8 +/- 0.8 mM) and 
TbHK1:V468A (1.9 +/- 0.7 mM) , however, differed by greater than ten-fold as 
compared to the value of TbHK1 (0.15 +/- 0.3 mM) (Figure 2.2B) (Table 2.1).  
 53 
 
The kcat values for variants TbHK1:I458V, TbHK1:V468A, and TbHK1:D470G 
with respect to glucose were similar to wild-type TbHK1 with the wild-type value similar 
to a previously reported value for the wild-type protein [5]. Likewise, the differences in 
Table 2.1. Kinetic Characterization of TbHK1 and TbHK1 C-terminal Tail Mutants 
  Apparent Km (mM)
a
  
Protein Glucose ATP Mg
2+
 Mannose Fructose 
TbHK1 0.06 ± 0.04 0.28 ± 0.1 0.98 ± 0.25 0.02 ± 0.01 0.15 ± 0.3 
TbHK1:D470G 0.03 ± 0.03 0.25 ± 0.05 0.2 ± 0.06 0.007±0.002 0.5 ± 0.2 
TbHK1:N469D ND ND ND ND ND 
TbHK1:V468A 0.10 ± 0.03 0.077 ± 0.048 0.4 ± 0.05 0.02 ± 0.01 1.9 ± 0.7 
TbHK1:M466I ND ND ND ND  ND 
TbHK1:F462L ND ND ND ND ND 
TbHK1:I458V 0.04 ± 0.01 0.068 ± 0.024 0.6 ± 0.07 0.01 ± 0.02 3.8 ± 0.8 
TbHK1:S456A ND ND ND ND ND 
TbHK1:D454G ND ND ND ND ND 
a Data are means ± standard deviations, ND, as activity was not detected 
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Figure 2.2 Wild-type and mutant enzyme activity using glucose or fructose as substrate.  (A) 
Kinetic curves of TbHK1 and TbHK1 mutants using glucose as a substrate.  Triplicate sets of standard 
reactions were performed as described under “Materials and Methods”.  TbHK1 (), TbHK1:D470G 
(), TbHK2 (), TbHK1:N469D (), and no protein control ().  Assays with TbHK2 and 
TbHK1:N469D were performed using ten times more protein than in the TbHK1 assay.  Assays are 
representative of experiments done using three different protein preparations.  (B.) Kinetic curves for 
rTbHK1 with fructose as substrate.  Please note that assays were performed at 50 mM fructose (which 
was saturating for all variants) and this data was not included to allow resolution of the curves at lower 
substrate concentrations.  TbHK1 (), TbHK1:D470G (), TbHK1:I458V (), and TbHK1:V468A 
(). 
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kcat values for ATP were less than two-fold increased for the three enzyme variants. 
Residues D454, F462, M466, and N469 are necessary for catalytic activity of TbHK1. 
Single mutations in TbHK1 to yield protein harboring the remaining differences 
in the C-terminal tails of TbHK1 and TbHK2 (TbHK1:D454G, F462L, M466I and 
N469D) resulted in catalytically inactive TbHK1, even when reactions were performed 
with ten-fold more protein (Figure 2.2A, Table 2.1).  D454, which is found in the loop 
region N-terminal to α-13 (Figure 2.1B), is part of the HXKα13HELIX motif mentioned 
above (Figure 2.1A).  Residues F462, M466, and N469 are predicted to reside on the 
same face of α-13 (Figure 2.1B).  
I458 and V468 of TbHK1 together are required for HK activity.   
Our previous efforts revealed that replacement of the TbHK2 C-terminus with the 
TbHK1 C-terminus yields an active HK [5], indicating that alteration of all seven residue 
differences restores HK activity to TbHK2.  To refine our understanding of the 
contribution of these residues, we first made single mutations in TbHK2 in an effort to 
restore HK activity. 
The lone difference between TbHK2 and other eukaryotic HKs at residue 454 
suggested that generating a TbHK2:G454D variant might restore activity of the protein.  
Following expression and purification, this soluble protein remained inactive like the 
parent polypeptide.  Additionally, mutating individual residues L462, I466, and G470 of 
TbHK2 to the corresponding residue in TbHK1 did not restore HK activity.  
Recombinant variants harboring multiple changes, including TbHK2:3HelixMUT 
(L462F, I466M, and D469N) and TbHK2:4TailMUT (G454, L462F, I466M, and 
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D469N), were not sufficient to restore catalytic activity to TbHK2.  TbHK2:5TailMUT 
(G454D, L462F, I466M, D469N, and G470D mutations), which has a tail sequence that 
would be equivalent to a TbHK1:I458V/V468A double mutant, was also inactive. This 
was notable, as the single residue variants TbHK1:I458V and TbHK1:V468A were active 
HKs (Table 2.1), albeit with lower affinity for fructose.  
Discussion 
TbHK1 and TbHK2 are 98% identical at the amino acid level, with 7 of the 10 residue 
differences found within the terminal 18 amino acids of the polypeptides [5].  Modeling 
TbHK1 and TbHK2 to yeast and S. mansoni HK revealed that this C-terminal domain lies 
between the larger and smaller lobes of the TbHKs in a region that may be serving as the 
hinge for movement of the lobes upon substrate binding [5]. 
TbHK1 and TbHK2, like other HKs, harbor an actin fold motif implicated in ATP 
binding.  The C-terminal tails of TbHK1 and TbHK2 are homologous to the CONNECT2 
domain of this motif [7, 8].  Consistent with the C-terminal tail of the TbHKs 
participating in ATP binding, two of the three active TbHK1 tail mutants have an altered 
affinity for ATP (TbHK1:V468A and TbHK1:I458V, with apparent Km values 3.6 and 
4.1 lower, respectively, than the wild-type enzyme (Table 2.1)).  Interestingly, mutations 
within the CONNECT2 region (residues 452-464 of TbHK1 and 2) also impact the 
affinity for fructose (Table 2.1).  Alteration of I458 yielded TbHK1 enzyme with a 
marked decreased affinity for fructose.  Changes in the tail beyond the CONNECT2 
motif also altered substrate binding, with TbHK1:V468A demonstrating a loss of fructose 
affinity.  These observations suggest that residues within and external to the CONNECT2 
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helix may influence the overall structure of the substrate binding pocket in addition to 
ATP binding.  In agreement with this suggestion, yeast Hxk2 variants lacking the 10 C-
terminal residues have a 3-fold increase in Km for fructose and a decrease in glucose 
phosphorylation activity [12].  Other changes within the CONNECT2 domain of TbHK1 
(to the corresponding residues in TbHK2, D454G and F462L) abolished detectable HK 
activity, again implying that residues within the CONNECT2 helix may influence the 
overall structure of the substrate binding pocket.  
The C-terminal tails could be playing roles in enzymatic function in addition to 
those attributed to the CONNECT2 domain.  Modeling suggests that the C-terminal tail 
could be influencing TbHK1 and TbHK2 function by altering the positioning of a 
catalytic base, D214. The α-13 of TbHK1 and TbHK2 are proximal to the catalytic base 
D214 (Figure 2.1B) suggesting that the tail may be involved in the positioning of this key 
residue.  In TbHK1, the side chain of D214 is oriented upward into the active site while it 
is pushed down and away from the active site in TbHK2 (Figure 2.3).  After modeling 
TbHK1:N469D, an inactive TbHK1 variant, to S.cerevisiae PII HK, we observed a 
similar rotation of D214 in the mutant polypeptide (Figure 2.3). These models also 
revealed that the closest C-terminal tail residue to D214 is S456, whose position is 
influenced by the structure of the tail.  In TbHK1, the γ-carbon of D214 is modeled to be 
5.2Å from the hydroxyl group of S456, while in TbHK1:N469D and in TbHK2, these 
atoms were more closely positioned (3.5 and 3.6 Å, respectively).  This residue may be 
involved in positioning D214 for nucleophilic attack on the C6 of glucose by the γ-
phosphate of ATP.   Interestingly, single amino acid changes in TbHK1 (to the 
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corresponding residue in TbHK2) within the C-terminal tail can alter the overall 
architecture sufficiently to trigger repositioning of S456 (and therefore D214).  In the 
inactive TbHK1:N469D mutant, for example, S456 is positioned to deflect D214 away 
from the active site (Figure 2.3).  
 
Structural studies on mammalian glucokinase may also provide clues into the role 
of the C-terminal tails in TbHK1 and 2.  Crystal structure studies on mammalian HK 1, 
glucokinase (HK IV), and yeast HK, indicate that binding substrate leads to a rotation of 
the lobes from an open to closed form [9, 13-16].  Unlike the other HKs, however, 
unbound glucokinase takes a “super open form”, extruding the α-13 helix from the small 
domain to be repositioned between the two lobes of the protein [17].  It is possible that 
 
 
Figure 2.3 Positioning of the catalytic residue D214 in response to differing C-terminal sequences of 
TbHKs.  TbHK1, TbHK1:N469D, and TbHK2 were modeled to S.cerevisiae HK PII.  Residues indicated 
include S456 (blue), D214 (red), and essential residues in yellow. 
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the different C-terminal tail composition allows TbHK1 to be repositioned when 
substrate is bound while TbHK2 is maintained in the open form in order to carry out a 
cellular function that is yet to be identified.   
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Abstract 
Glycolysis is essential to the parasitic protozoan Trypanosoma brucei.  The first step in 
this metabolic pathway is mediated by hexokinase, an enzyme that transfers the γ-
phosphate of ATP to a hexose.  The T. brucei genome (TREU927/4 GUTat10.1) encodes 
two hexokinases (TbHK1 and TbHK2) that are 98% identical at the amino acid level.  
Our previous efforts have revealed that TbHK2 is an important regulator of TbHK1 in 
procyclic form parasites.  Here, we have found through RNAi that TbHK1 is essential to 
the bloodstream form parasite.  Silencing the gene for four days reduces cellular 
hexokinase ~60% and leads to parasite death.  Additionally, we have found that the 
recombinant enzyme is inhibited by lonidamine (IC50 = 850 µM), an anti-cancer drug that 
targets tumor hexokinases.  This agent also inhibits HK activity from whole parasite 
lysate (IC50 = 965 µM). Last, lonidamine is toxic to cultured bloodstream form parasites 
(LD50 = 50 µM) and procyclic form parasites (LD50 = 180 µM).  Interestingly, 
overexpression of TbHK1 protects PF parasites from lonidamine.  These studies provide 
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genetic evidence that TbHK1 is a valid therapeutic target while identifying a potential 
molecular target of the anti-trypanosomal agent lonidamine. 
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Introduction  
Trypanosoma brucei rhodesiense and T.b.gambiense are the causative agents of African 
human sleeping sickness, while T.b.brucei causes the wasting disease nagana in cattle.  
The human disease has recently re-emerged as a major cause of illness in sub-Saharan 
Africa, leading the WHO/TDR (WHO special programme for research and training in 
tropical diseases) to classify the infection as a category 1 (re-emerging, uncontrolled) 
disease [1].  Unfortunately, all drugs currently used in the treatment of human African 
trypanosomiasis can have adverse side effects, including encephalopathy and death [2].   
 Ideal targets for drug development include essential metabolic pathways like 
glycolysis.  Bloodstream form (BSF) parasites generate energy exclusively through the 
metabolism of carbohydrates using this pathway, suggesting that specific inhibitors of T. 
brucei glycolytic enzymes could be potent therapeutics.  To that end, TbHK1, the first 
enzyme in glycolysis, has been targeted by structurally-based TbHK inhibitors that were 
trypanocidal, albeit at high concentrations [3].   
 Lonidamine (LND, 1-(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid) is a drug 
that was originally developed as an antispermatogenic reagent [4].  More recently, LND 
has been found to be effective against cells with high metabolic needs, including some 
cancers and parasites.  In tumors, LND interferes with cellular energy production by 
inhibiting mitochondrial-bound HK and mitochondrial electron transport [5, 6], leading to 
apoptosis [7-9]. 
 The impact of LND on protozoan parasites has also been explored, in part because 
the importance of glucose metabolism in these cells suggested that the drug might be a 
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potent anti-parasitic compound.  LND was found to be toxic to the model trypanosome 
Trypanosoma lewisi in culture, yielding an LD50 ~260 µM.  Additionally, the compound 
reduced parasitemia in infected rats [10].  In this case, the molecular target was unknown.  
LND has also been shown to be effective against Leishmania mexicana promastigotes 
and T. cruzi epimastigotes, with LD50s of ~260 µM and ~80 µM, respectively [11, 12].  
In both L. mexicana promastigotes and T. cruzi epimastigotes, respiration was inhibited.  
However, the HK from T. cruzi lysate was insensitive to LND [12]. 
 African trypanosomes were also impacted by LND, with PF parasite respiration (a 
measure of glycolysis in this system) inhibited ~50% by 90 µM LND.  BSF 
trypomastigotes were not as sensitive, with a Ki for respiration inhibition of 400 µM 
LND [12].  The toxicity of this compound to either lifestage was not reported and the 
molecular target was not identified.   
 Here we report that LND inhibits recombinant TbHK1 and HK activity from T. 
brucei lysates, suggesting that one of the targets of the compound could be HK.  As one 
would expect for an essential gene, we demonstrate the toxicity of this compound to BSF 
trypanosomes, which suggests that this drug could prove to be useful in the development 
of new anti-trypanosomal therapies. 
Materials and Methods  
Reagents  
Lonidamine (LND, 1-(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid) was purchased 
from Sigma-Aldrich (St.Louis, MO) 
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Trypanosome cell culture and transfection  
BSF parasites (cell line 90-13, a 427 strain) were grown in HMI-9 supplemented with 
10% fetal bovine serum and 10% Serum Plus (Sigma-Aldrich, St.Louis, MO).  The T7 
RNA polymerase and the tetracycline repressor constructs were maintained by the 
addition of 2.5 µg/ml G418 and 5 µg/ml hygromycin to the medium.  Parasites were 
transfected and selected as described [13].  RNAi specific for TbHK1 was performed by 
targeting the unique 3’UTR of the transcript.  Briefly, the 3' UTR TbHK1 was targeted by 
a 341 bp fragment previously identified as a 3' untranslated region sequence starting 397 
bp downstream of TbHK1 on chromosome 10 [14].  TbHK2 expression was silenced 
using a 338 bp fragment of the 3’ UTR in pZJM that is 12 bp downstream of the stop 
codon of TbHK2.  For each transfection, BSF parasites were grown to mid-log phase (~5 
× 105 cells/ml) and 1 × 108 cells transformed with NotI linearized pZJM as described 
[13].   
PF 29-13 and TbHK2-deficient (TbHK2-/- [15]) T. brucei were grown in SDM-79 
[16, 17] or SDM-80 supplemented with 9% heat-inactivated dialyzed serum (Sigma) and 
1% heat-inactivated serum.  Parasite growth was monitored on a Becton-Dickinson 
FACScan flow cytometer.   
For studies exploring the impact of overexpression of TbHK1 in PF cells, parental 
cells PF 29-13 were transformed with linearized pLew111(2T7)GFPβ [18] harboring the 
TbHK1 gene.  This vector fused the green fluorescent protein (GFP) to the carboxyl 
termini of expressed proteins. TbHK1 expression was induced in PF 29-13 cells 
harboring pLew111(2T7)TbHK1 by addition of tetracycline (1 µg/ml) the media.  
 68 
Assays of recombinant and lysate-derived HK  
Recombinant TbHK1 was expressed and purified as previously described [15].  
Parasite lysates were prepared by hypotonic lysis of 1 x 107 cells in the presence of 1 mM 
PMSF, 20 µg/ml leupeptin, and 100 µg/ml TLCK.  The mixture was then mixed with 
lysis buffer (to a final concentration of 0.1 M triethanolamine (TEA) pH 7.4 and 0.1% 
Triton X-100) and lysates used in HK assays. 
Hexokinase assays were performed in triplicate using a coupled reaction.  Briefly, 
assays used glucose 6-phosphate dehydrogenase (1 unit/assay, EMD Biosciences, Inc, 
Sand Diego, CA) as a coupling enzyme to reduce NADP+ to NADPH during the 
oxidation of G6-P to 6-phosphogluconic acid.  Final conditions were 0.1M TEA, pH 7.9 
containing 1.0 mM ATP, 33 mM MgCl2, 20 mM glucose, and 0.75 mM NAD
+. Assays 
were performed in 96-well microtiter plate format in a GENios spectrophotometer 
(Phenix Research Products, Hayward, CA).   
To confirm inhibition an alternative coupled reaction was used that measures HK 
consumption of ATP to ADP.  The ADP produced drives the conversion of PEP to 
pyruvate by pyruvate kinase (1 U, EMD Biosciences, Inc).  Lactate dehydrogenase (1 U, 
EMD Biosciences, Inc) metabolizes pyruvate to lactate, a reaction that requires the 
oxidation of NADH to NAD+, which can be monitored spectrophotometrically at 340 nm.  
Inhibitors were preincubated with HK (30 min, 25oC) in 0.1M TEA, pH 7.9, 
supplemented with 12 mM MgCl2, 1 mM DTT, 4 mM ATP, and varying concentration of 
inhibitor or equivalent volumes of the solvent used to solubilize the inhibitor and the 
incubation reaction assayed for hexokinase activity.  Inhibitors tested here did not 
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interfere with absorbance measurements.  Kinetic analyses were performed using 
KaleidaGraph 4.1 (Synergy Software, Reading, PA) with the Michaelis-Menton curve fit 
algorithm.  
Results  
Previously, we explored the role of TbHK1 in PF parasites primarily using reverse 
genetic approaches, including RNAi and attempted gene knockouts.  RNAi of TbHK1 led 
to decreased cellular HK activity and altered surface molecule expression, but cells 
remained viable in culture [14].  Interestingly, our inability to generate homozygous null 
TbHK1 cells suggests that TbHK1 plays an essential role in the biology of PF parasites 
(M. Morris and J. Morris, in preparation).   These results differ from RNAi likely due to 
the greater penetrance of the knockout.   
TbHK1 is essential to BSF parasites.  
Using pZJM-mediated RNAi to target the distinct 3’UTR of TbHK1, we 
monitored the impact of gene silencing on BSF growth and hexokinase activity (Figure 
3.1).  BSF parasites in which TbHK1 was silenced began to die after two days but by day 
5 the cells had recovered and escaped RNAi, a phenomenon previously described in T. 
brucei (Figure 3.1).  Further, silencing TbHK1 for 4 days led to a 60% decrease in the 
amount of hexokinase activity per cell compared to parental cells (Figure 3.1, insert).   
These results are distinct from those reported by Albert et al., as their efforts targeted the 
second HK (TbHK2) and identified it as essential to BSF parasites [19]. 
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LND inhibits rTbHK1 and HK activity from whole parasite lysates 
The genetic validation that TbHK1 is potentially a suitable drug target led us to 
explore the impact of a number of known HK inhibitors and drugs on rTbHK1 activity.  
 
   
Figure 3.1  RNAi of TbHK1 is lethal to BSF trypanosomes. (A) The growth profile of a tetracycline-
induced clone harboring pZJM(TbHK13’UTR) in the presence of 1 µg/ml tetracycline () was 
compared with that of untransfected parental 90–13 cell line ().  Cell densities were determined using 
a BD FACScan and cell numbers plotted with the cytometer set to score all events, which may not 
discriminate between living and some dead cells, leading to a conservative assessment of RNAi 
toxicity.  The data presented here are representative of 3 independent experiments. Insert, HK activity 
after RNAi of TbHK1. Parental (PF 90-13) or parasites harboring pZJMTbHK13’UTR (uninduced and 
induced 4 days) were grown in HMI-9 supplemented with G418 (1.5 µg/ml), hygromycin (5 µg/ml), 
and phleomycin (2.5 µg/ml).  Cellular HK activity from detergent lysates of 1 x 106 cell equivalents was 
assessed. 
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LND is a potent anti-cancer drug that has been shown to inhibit mammalian tumor HK.  
Against rTbHK1, LND was inhibitory with an IC50 of 850 µM (Figure 3.2A).  Inhibition 
was non-competitive with respect to ATP and glucose yielding a Ki of 84 µM and 57 µM, 
respectively.   
Other HK inhibitors, including glucose-6-phosphate, 5-thio-D-glucose, and 3-
methoxyglucose, did not inhibit rTbHK1 (not shown).  Additionally, the bisphosphonates 
risedronate, C175, C173, C176, C178, SSA178, SSB13, SSB11, BR25, BR18, and BR11 
(the generous gift of Drs. Juan Bautista Rodriguez, Universidad de Buenos Aires and 
Roberto Docampo, the University of Georgia), a class of compounds that have been 
shown to be potent inhibitors of T. cruzi HK, did not inhibit rTbHK1 [20, 21].  
To determine if LND could also inhibit authentic HK from T. brucei, we tested 
the compound against BSF cell lysates.  In assays using 5 x 105 BSF cell equivalents, 
LND inhibited HK activity in a dose-dependent manner, with an IC50 of 965 µM (Figure 
3.2B).   
LND is toxic to BSF parasites 
LND has previously been shown to inhibit energy metabolism in T. cruzi epimastigotes 
and Leishmania mexicana promastigotes, leading to toxicity in those species [11, 12].  
LND has also been explored as a metabolic inhibitor of T. brucei trypomastigotes and 
procyclic trypomastigotes, though the impact of the drug toxicity on these lifecycle stages 
was not reported [12].  Given our success in inhibiting an essential enzyme with LND, 
we next determined the toxicity of the compound to BSF parasites.  After 48 hours of 
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growth in the presence of LND, cell growth was repressed 50% by 50 µM of the drug 




LND toxicity to PF parasites is tempered by overexpression of TbHK1 
  
    
Figure 3.2  LND inhibits rTbHK1 and HK activity from BSF cell lysate.  Increasing amounts (0-5 
mM) of LND were incubated with (A) rTbHK1 (160 ng/assay) or (B) 5 x 105 BSF cell equivalents for 
30 min at RT and HK assays were performed as described in the Materials and Methods. 
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PF parasites were sensitive to LND as well even though their metabolism is more 
flexible than BSF parasites.  While LND is toxic to PF grown for 48 hours in glucose-
rich medium (LD50 = 180 µM), adaptation of the PF parasite to amino acid metabolism   
by growth in very low glucose was protective, a phenomenon seen for other trypanocidal 
drugs that target glycolysis [22].  Under these conditions, the LD50 was increased to ~575 
µM (Figure 3.3B).  PF parasites lacking TbHK2 (TbHK2-/-) were similarly sensitive to 
LND (Figure 3.3B), suggesting that it is not the most likely target of LND in PF 
parasites.   
 Interestingly, overexpression of TbHK1 limited the toxic effects of LND on PF 
parasites.  Treatment of parental parasites with a high concentration (500 µM) LND for 
36 hours led to a 75.5% reduction in parasite number (Figure 3.4).  Parasites induced to 
over-express TbHK1 for two days had ~2.1-fold greater cellular HK activity (Figure 3.4, 
inset) and were more resistant to LND, with a 48.6% reduction in parasite number.  
Please note that the TbHK1-expressing cells grew more slowly and were more irregularly 
shaped than the parental cells (hence the difference in absolute cell number in Figure 
3.4), suggesting that overexpression of TbHK1 was detrimental to the cell.  Nevertheless, 
these parasites survived the added insult of LND treatment more readily than did the 






      
 
Fig.ure 3.3 LND is toxic to cell growth. (A)  BSF trypanosomes grown in triplicate in HMI-9 
medium were incubated for 48 hr with increasing amounts of LND and densities determined by 
counting as described and plotted as a percentage of control untreated cells.  Error bars are too 
small to be visible. (B)  PF 29-13 (circles) or TbHK2 knockout cells (squares) adapted to growth 
without (open symbols) or with (filled symbols) glucose (10 mM) prior to addition of LND.  Cells 
were incubated with inhibitor for 48 hr prior to counting.  The LD50 for cells grown in SDM-80 






Figure 3.4 Overexpression of TbHK1 alters PF LND sensitivity.  Parental PF trypanosomes (29-13) 
or parasites transformed with pLEW111(2T7):TbHK1 induced for two days to express TbHK1 were 
grown in the presence of 500 µM LND for 36 hours and cell densities determined.  Results are from 
three experiments.  (Inset) Hexokinase activity of parental PF trypanosomes (29-13) or parasites 
transformed with pLEW111(2T7):TbHK1 induced for two days was determined from total cellular 
lysates.   
Discussion 
Glycolysis serves as the sole source of energy for the bloodstream form of the parasitic 
protozoan Trypanosoma brucei.  Interest in inhibiting this pathway has led us to validate 
TbHK1 as a candidate for therapeutic development. 
With the completion of the T. brucei genome sequencing project, we learned that 
in the T. brucei strain 927 genome, there are two HK genes, TbHK1 and 2, encoded in 
tandem on chromosome 10 that are predicted to yield 51 kDa proteins that are 98% 
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identical [14].  The gene for TbHK1 had been previously cloned and partially 
characterized, revealing that the protein shares 30-33% amino acid identity with HKs 
from yeast, plants, and mammalian glucokinase (type IV hexokinase, which is closer in 
size to TbHK1 than types I-III) [3].  The unique nature of its oligomers and catalytic 
properties distinguishes TbHKs from other HKs, making them promising drug targets. 
Initial RNAi studies in PF parasites suggested that neither TbHK1 nor TbHK2 
were essential though TbHK1 was likely the source of the majority of the HK activity in 
PF cells [14].  RNAi of TbHK2 yielded cells indistinguishable from parental parasites. 
Since PF parasites can up-regulate amino acid metabolism in the absence of substrates for 
glycolysis, it was proposed that PF parasites could tolerate silencing of the TbHKs (and 
other glycolytic enzymes) [14].  Of note, these studies were likely complicated by the 
incomplete penetrance of the RNAi, as follow up knockout studies have produced cells 
with profound phenotypes.  TbHK1 homozygous null parasites have not (to date) been 
obtained, which is not surprising given the severe growth defect observed in the 
heterozygous null parasites (M.T. Morris and J.C. Morris, unpublished).  TbHK2 
homozygous null PF parasites overexpress TbHK1 and have and increase in hexokinase 
activity, suggesting TbHK2 serves as a regulator of TbHK1 expression and activity [15].  
Because BSFs utilize only glycolysis for energy, it is not surprising that RNAi of 
the main enzymatic HK (TbHK1) is toxic to the parasite (Figure 3.1).  Interestingly, we 
have found that silencing TbHK2 is also lethal to BSF (data not shown), in agreement 
with previously published work, which also revealed that TbHK2 contributes to the total 
cellular HK activity in BSF parasites [19].   
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These genetic observations suggest that the TbHKs are suitable candidates for 
drug target development.  Because many tumors have enhanced rates of glycolysis, 
inhibiting glycolysis has also been suggested as a mechanism for cancer therapy.  This 
has led to the development and testing in humans of a number of drugs that target tumor 
metabolism.  One such compound, LND, has been used alone or in combination with 
other drugs to treat a spectrum of tumors, including breast, and head and neck cancers 
[23, 24].  While the mode of action of LND is not completely understood, it interferes 
with cellular energy production by inhibiting mitochondrial HKs [5] and mitochondrial 
electron transport [6], and can trigger apoptosis [9]. 
 LND also has activity against a number of protozoa, including T. lewisi, L. 
mexicana promastigotes, and T. cruzi epimastigotes, [11, 12].  The mode of action in 
each of these parasites may be different.  For example, T. cruzi HK in whole cell lysate, 
unlike the T. brucei activity, is not inhibited by LND [12].  While the parasites are highly 
related, the two enzymes are distinct.  The T. cruzi enzyme is inhibited by acyl-CoAs and 
5-thioglucose (Ki = 400 µM)[25, 26], while TbHK1 is not inhibited by either (but is 
inhibited by free fatty acids [15]). 
Our in vitro studies indicate that LND is toxic to BSF strain 427 parasites with an 
LD50 of 50 µM. The notable difference between the IC50 for TbHK1 (850 µM) and the 
LD50 for cell killing suggests that the compound may have off-target effects in the cells. 
Supporting this possibility, in mammals LND is known to inhibit other enzymes in 
addition to HKs including the mammalian CFTR chloride channel [27].  Alternatively, 
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the discrepancy between the two values could result from the concentration of LND 
within the cells (perhaps in the glycosome) or metabolism of LND to a more potent form.   
Why is LND toxic to PF parasites, given their flexible metabolism that allows 
them to utilize both glucose and amino acids as energy sources?  Further, why is RNAi of 
TbHK1 tolerated in PF while LND (if it is indeed inhibiting TbHK1) toxic?  We propose 
that LND rapidly causes inhibition of glycolysis, which has been shown to be toxic to PF 
cells.  As an example, inhibition of glycolysis using the adenosine analog tubercidin is 
toxic to PF parasites [22].  However, cells are protected from tubercidin if they are 
allowed to adapt to low glucose conditions (and presumably increase energy production 
for other metabolic sources) prior to tubercidin treatment, similar to our LND 
experiments in PF parasites.  RNAi, which can require days to sufficiently deplete 
abundant or stable proteins for development of a phenotype, may be slow enough to 
allow the cell to up-regulate other metabolic pathways. 
In a rat model system, a single treatment of orally delivered LND (100 mg/kg) 
resulted in serum concentrations of 3-37.3 µM LND after 48 hr [28].  In humans, LND 
treatment for 30 days (450 mg oral treatments/day, which is well tolerated) provided peak 
plasma levels of 14-105 µM LND [29].  These correlations suggest that further animal 
studies are warranted to determine the effectiveness of LND in vivo.  
 The data presented here suggests that LND could be toxic to T. brucei as a result 
of inhibiting TbHK activity.  This hypothesis is supported by both the increased LND 
resistance observed in PF parasites adapted to amino acid metabolism (and therefore less 
reliant on glycolysis) (Figure 3.3B) as well as the increased tolerance observed in the 
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TbHK1 over-expressing parasite line.  While the HK studied here is from a strain that is 
not pathogenic to man, inhibitors of this model enzyme may be useful in the development 
of therapeutic compounds for human infective strains.  T. b. gambiense, for example, 
harbors a HK gene predicted to encode a protein that is nearly identical (one amino acid 
difference that may result from a single nucleotide sequencing error) to TbHK1. 
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CHAPTER FOUR 
OLIGOMERIZATION OF RECOMBINANT TBHK2 WITH TBHK1 ACTIVATES 
THE HEXOKINASE. 
Jeremy W. Chambers, Meredith T. Morris, and James C. Morris1 
Department of Genetics and Biochemistry 
Clemson University 
Clemson, SC 29634 
Abstract 
Trypanosoma brucei relies on glycolysis for ATP generation in the mammalian 
bloodstream.  T.brucei has two hexokinases, TbHK1 and TbHK2, which are 98% 
identical at the amino acid level.  We found previously that recombinant TbHK1 
(rTbHK1) has HK activity, while rTbHK2 lacks detectable activity, a difference 
attributed to amino acid difference within the C-terminal ends of the proteins.  Unlike 
many HKs, ADP and glucose-6-phosphate do not inhibit TbHK1.  However, the enzyme 
was inhibited by myristate, a fatty acid that is important to T. brucei.   
We report here that myristate is an uncompetitive inhibitor with respect to glucose 
and ATP (Ki = 50 µM and 80 µM, respectively).  Further, myristate was able to 
disassemble recombinant TbHK hexamers in a substrate-dependent manner.  The 
oligomers were dissociated into monomers when incubated with myristate, a dissociation 
that was reversible upon removal of myristate.  Mixing of monomeric TbHK1 and 
TbHK2, followed by reassembly by removal of myristate generated TbHK1/TbHK2 
heterohexamers with a 4-fold increase in specific activity compared to TbHK1 alone.  
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Last, reassembly of TbHK2 with an inactive TbHK1 mutant, TbHK1:S160A, revealed 




 The African trypanosome, Trypanosoma brucei, is the causative agent of human 
African sleeping sickness and nagana in livestock.  The parasite has developed a complex 
lifecycle to exploit the different environments of its two hosts, a mammal and the tsetse 
fly.  In the fly, T. brucei has a metabolism that relies largely on amino acid metabolism, 
with the mammalian bloodstream form (BSF) parasites have an inactive mitochondrion 
and they rely exclusively on glycolysis for energy. 
 The T. brucei genome encodes two hexokinases, TbHK1 and TbHK2, which are 
98% identical at the amino acid level. Studies on recombinant proteins have 
demonstrated that recombinant TbHK1 is a catalytically active hexokinase, while 
recombinant TbHK2 lacks any detectable hexokinase activity[1].  These catalytic 
differences were attributed to the final 18 residues of the polypeptides, where seven of 
the ten amino acid differences between the two proteins are found. 
 Characterization of recombinant TbHK1 revealed that the polypeptide could use 
glucose, mannose, fructose, 2-deoxy-D-glucose, and glucosamine as substrates [1].  ATP 
and UTP served as phosphate donors, and Mg2+ was the preferred divalent ion. While the 
enzyme was not inhibited by its product (Glc-6-P), TbHK1 was found to be inhibited by 
free fatty acids [1].  Myristate and palmitate were found to be the most potent inhibitors 
with IC50s of 78 and 63 µM, respectively. 
 Myristate and palmitate are very important fatty acids in T. brucei.  Palmitate is 
the most abundant fatty acid in the procyclic (fly) form (PF) of the parasite while 
myristate is the most abundant fatty acid found in the BSF trypanosome [2].  The 
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dominant surface molecules in T.brucei are attached to the membrane by 
glycosylphosphatidylinositol (GPI) anchors containing these fatty acids [3].  The BSF 
parasite has 107 molecules of the variant surface glycoprotein (VSG) on their surface and 
these require two myristate molecules per anchor (for a total of 2x107 myristate 
molecules per parasite surface).  
Because HKs function in the first step of glycolysis, an essential pathway in the 
infective stage of the life cycle, understanding the enzymology and regulation of these 
proteins is crucial to understanding energy metabolism in T. brucei.  Here we have 
investigated how rTbHK1 is inhibited by medium-length free fatty acids, including the 
impact of myristate on oligomerization.   These studies provide insight into the function 
and composition of TbHK oligomers and their impact on enzyme activity. 
Materials and Methods 
TbHK assays and myristate inhibition 
Recombinant TbHKs, rTbHK1, rTbHK2, and TbHK1:S160A were expressed 
from pQE30 (Qiagen, Inc., Valencia, CA), transformed into M15(pREP) E. coli, and 
purified as described in [1].  
HK assays and inhibitor studies were performed as described [1]with the 
modification that kinetic analyses were performed using KaledaGraph 4.1 (Synergy 
Software, Reading, PA) with the Michaelis-Menton curve fit algorithm.  Inhibitors were 
studied using a glucose-6-phosphate dehydrogenase coupled HK assay [1] in which the 
product of HK (glucose-6-phosphate) is oxidized to 6-phosphogluconate by glucose-6-
phosphate dehydrogenase (G6PDH) resulting in the concomitant generation of NADPH 
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which is monitored at 340 nm.  To determine the Ki of rTbHK1 for myristate, ~200 ng of 
rTbHK1 was incubated (1 hr, RT) in 10x inhibition buffer (10 mM Triethanolamine, pH 
7.4 and 1 mM DTT) containing either 10 mM glucose or 5 mM ATP/Mg2+ with 
increasing amounts of myristate (0 to 500 µM).  HK assays containing increasing 
concentrations of glucose (0 to 5 mM) or ATP (0 to 2 mM) were then performed for each 
myristate concentration.  The type of inhibition was determined using a double reciprocal 
plot of the velocity and substrate concentration for each myristate concentration.  
Native and 2-D Gel Electrophoresis of rTbHK1 
Native gel electorphoresis of rTbHK1 was performed on 4% polyacrylamide gels 
(4% bis-acrylamide, 375 mM Tris-HCl pH 8.8, 0.05% (v/v) TEMED, 0.05% APS) 
resolved in a Tris-glycine buffer (2.7 mM Tris-HCl, 192 mM Glycine, pH 6.9). Samples 
(~ 50 ng of protein) were diluted in native gel loading buffer (10% (v/v) glycerol, 2.7 
mM Tris-HCl pH 6.8, and 0.1% bromophenol blue) and resolved. Following 
electrophoresis, gels were silver stained using the Pierce SilverSNAP Stain Kit II 
Protocol (Pierce, Rockford, IL).  
The molecular masses of the components released from rTbHK1 oligomers 
following myristate treatment was determined using two dimensional gel electrophoresis, 
where the first dimension was a 4% native gel and the second was a 10% SDS-PAGE gel. 
The 4% gels were run as described above.  Lanes of the 4% native gel were excised, 
placed on the stacking gel of a 10% SDS-PAGE, and overlaid with 5 x SDS-PAGE 
loading buffer, and proteins resolved.  
Western Blotting of rTbHK1 Native Gels 
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Following resolution on native gels, proteins were transferred in Tris-glycine buffer to 
nitrocellulose pre-equilibrated in the same buffer.  Membranes were blocked with 1% 
nonfat milk in 1 x TNT (5 mM Tris-HCl pH 8.0, 75 mM NaCl, 0.025% Tween) prior to 
incubation with mouse anti-RGS6His antibody (Qiagen, 1:2000, 1 hr, RT).  Following 
washes in 1 x TNT (3 x 5 min, RT), goat anti-mouse conjugated to horseradish 
peroxidase (1:10,000) was added and incubated (1hr, RT) with the membrane. Secondary 
antibody staining was detected using the Supersignal West Pico Chemiluminescent 
Substrate Kit protocol (Pierce, Rockford, IL). 
In-gel HK Assay 
Following electrophoresis, native gels were washed in ultrapure water (5 min, RT) and 
then incubated in the dark (15 min, RT) with 3 units/mL G6PDH , 0.02 mg/mL 
phenozine methosulfate, 0.2 mg/mL nitroblue tetrazolium, and 0.3 mM NADP in HK 
assay buffer (45 mM Tris-HCl pH 9.5, 5 mM glucose, 3 mM MgCl2, and 3 mM ATP).  
Gels were soaked in 10% acetic acid (15 min, RT) to quench the reaction.  Glucose-6-
phosphate, the product of HK, was evident by the precipitated nitroblue tetrazolium on 
the gel.  
Disassembly and Reassembly of Recombinant TbHK oligomers 
Recombinant hexokinases (TbHK1, TbHK2, and TbHK1:S160A) were incubated 
(1 hr, RT) in 10x inhibition buffer supplemented with 5 mM ATP/Mg2+ and 5 mM 
myristate or DMSO.  Myristate was removed by washing the sample in an Amicon Ultra 
Centrifugal filter Device with a 3,000 molecular weight cutoff. (Millipore Corp, Billerica, 
MA) after dilution in wash buffer (20 mM NaH2PO4, 0.5 M (NH4)2SO4, 0.1% Triton X-
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100, and 250 mM Imidazole) Seven volumes of wash buffer were added to proteins in the 
filter to remove myristate.  Oligomer disassembly was confirmed by native gel 
electrophoresis and the concentration of recovered protein was determined by Pierce 
BCA Kit (Pierce, Rockford, IL), with confirmation by coomassie stained SDS-PAGE gel.  
To reassemble oligomers, mixtures of myristate treated proteins were mixed together 
prior to washing on the Amicon filtration unit. 
Results 
Free fatty acids inhibit TbHK1 uncompetitively with respect to glucose and ATP 
Little is known concerning the regulation of T.brucei HK in vivo.  HK activity 
isolated from T. brucei (likely a mixture of TbHK1 and 2 in unknown stoichiometry) was 
not inhibited by its product [4].  Similarly, rTbHK1is not inhibited by either glucose-6-
phosphate or ADP. To investigate potential regulators, we explored rTbHK1 inhibition 
with a spectrum of metabolites. We analyzed amino acids (alanine, proline, glutamine, 
leucine, and threonine), carbohydrates (galactose, N-acetylglucosamine, and inositol), 
phospholipids (phosphatidylinositol, phosphatidylethanolamine, and phosphatidic acid), 
small molecules (lactate, malate, succinate, butyrate, glycerol, and acetyl-CoA), 
glycolytic intermediates (fructose-6-phosphate, fructose1,6 bisphosphate, pyruvate, and 
phosphoenol pyruvate), fatty acyl-CoAs and free fatty acids as potential TbHK1 
inhibitors.  None of these metabolites impacted rTbHK1 (~160 ng) activity at inhibitor 
concentrations of 10 mM, except for medium-length free fatty acids. 
Previously we found that medium to long chain (C10-C18) free fatty acids could inhibit 
rTbHK1, with myristate being the most potent [1].  To understand this observation more 
 92 
fully, we explored the nature of myristate inhibition and found that it is an uncompetitive 
inhibitor or rTbHK1 with respect to glucose and ATP (Ki of 50 and 70 µM, respectively) 
(data not shown).   
Myristate destabilizes TbHK oligomers  
TbHK activity has previously been isolated from T. brucei as a ~300 kDa 
hexameric protein complex [5].  Recombinant TbHK also oligomerize, as revealed by 
native gel electrophoresis.  Purified rTbHK1 and rTbHK2 migrate as ~300kDa 
complexes (Figure 4.1A, lane 1 and Figure 4.1A, lane 6).  This complex is not the result 
of covalent interaction, as the oligomer is disrupted by treatment with SDS (Figure 4.1A,  
lane 2).  Interestingly, incubation with myristate (500 µM) leads to a partial loss (~57%  
as judged by densitometer) of the complex (Figure 4.1A, lane 4), while incubation with 
stearate or decanoate (neither or which appreciably inhibit TbHK1 activity [1]) had little 
impact on the oligomers (Figure 4.1A, lanes 3 and 5).  Increasing the myristate 
concentration (to 50 mM) completely disrupted the complex, while control fatty acids 
only partly impacted the oligomers at that concentration (data not shown).  Enzyme 
assays of the SDS and myristate treated samples prior to native gel analysis (“%HK 
Activity in Solution”, Figure 4.1A) indicated that both treatments inhibited the enzyme 
activity (100% and 46%, respectively).  Oligomers of rTbHK2 were also disrupted by 





Figure 4.1 Impact of myristate on TbHK oligomers.  (A.) Native gel analysis of rTbHK1 (lane 1) and 
rTbHK2 (lanes 6) and the impact of treatment of proteins with 0.1% SDS (lane 2), 0.5 mM myristate (lanes 4 
and 7) 0.5 mM stearate (lane 3) and 0.5 mM decanoate (lane5).  The percent of oligomer remaining was 
determined by comparing the densitometry of silver stained bands in treated lanes (lanes 2-5) to that from 
untreated sample (lane 1), while the percent of HK remaining was determined by assaying HK in solution after 
the indicated treatments and then comparing the activity to untreated sample.  (B.) Native gel analysis of BSF 
(90-13) trypanosome lysate without (lane 1) or with incubation with 1 mM myristate (lane 2) or 10 mM 
lonidamine (lane 3). (C.) Western blotting of rTbHK1 treated with increasing (0-750 µM) myristate resolved 
by native gel.  (D.) 2-D electrophoresis of rTbHK1 untreated rTbHK1 (left) or myristate (1 mM) treated 
rTbHK1 (right). Proteins were resolved on 4% native gels that were then inserted into the stacking gel of a 
10% SDS-PAGE gel.  Proteins from the hexamer (single asterisk) or the monomer (arrow head) are indicated.  
The gels shown are representative of three experiments from two purifications of rTbHK1. 
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To determine if the myristate induced destabilization of oligomeric TbHK was 
specific for recombinant proteins, we explored the impact of myristate on HK from whole 
T. brucei lysates.  First, we incubated BSF lysates in the presence of myristate or 
lonidamine (a potent rTbHK1 inhibitor (J.W.Chambers and J.C. Morris, unpublished 
data)).  Lysates were then tested for HK activity.  Treatment with myristate (1 mM) and 
with lonidamine (10 mM) abolished HK activity in both cases (Figure 4.1B, “%HK 
Activity in Solution”).  A portion of the lysate was then resolved on 4% native gels and 
HK in-gel assays were performed.  Lysate from untreated parasite has HK activity that 
migrates on the native gel at a position consistent with a ~300 kDa complex (Figure 4.1B, 
lane 1). Interestingly, lysates treated with myristate lacked detectable activity at the ~300 
kDa position but instead had HK activity at ~50 kDa, consistent with migration of the 
monomer of the enzyme.  Lonidamine treated cell lysate yielded HK activity 
corresponding to a ~300 kDa species, suggesting lonidamine does not disrupt the 
complex.  Further, the HK activity of the ~300 kDa species suggests that lonidamine and 
the enzyme are separated during migration through the gel (or the inhibitor is washed out 
during the assay).  
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Figure 4.2  Substrate-dependent disassembly of TbHK oligomer.  Recombinant TbHK1 was treated 
with DMSO (Lane 2), 1 mM myristate (Lanes 3-5, top) or 10 mM Lonidamine (Lanes 3-5, bottom) in 
the presence of 5 mM ATP/Mg2+ (Lane 3), 5 mM glucose (Lane 4), or no substrate (Lane 5) in 
inhibition buffer. Samples were then resolved on 4% acrylamide native gels and silver stained. 
 
Myristate destabilizes rTbHK1 with a concomitant accumulation of monomers.  
While the ~300 kDa complex is not transferred efficiently, western blotting with an 
antibody to the N-terminal epitope tag revealed an increase in the abundance of the 
monomeric (~50 kDa) protein in response to increasing myristate (Figure 4.1C).  Further, 
two dimensional gel electrophoresis (native gel in the first dimension, denaturing gel in 
the second) revealed that untreated rTbHK1 migrates as a ~300 kDa complex that 
resolves into ~50 kDa species in the second dimension (indicated by *, Figure 4.1D).  
Incubation with myristate (1 mM) led to a decrease in ~50 kDa species arising from the 
~300 kDa complex (80% by densitometer) with a corresponding increase in a ~50 kDa 
species migrating in the first dimension at the dye front (indicated by ^, Figure 4.1D). 
Myristate-induced disassembly is substrate dependent 
To examine the impact of substrate presence on myristate-induced disassembly of 
hexameric rTbHK1, rTbHK1 was incubated in the presence or absence of myristate in 
buffers containing either ATP/Mg2+ or glucose and oligomer compared to enzyme 
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incubated with myristate in the absence of substrate.  Untreated purified rTbHK1, 
rTbHK1 incubated in DMSO (the solvent for myristate), and rTbHK1 incubated in 10x 
inhibition buffer (Figure 4.2, top row, lanes 1, 2, and 5 respectively) had similar amounts 
of ~300 kDa complex.  However, incubation with either ATP/Mg2+ or glucose and 
myristate led to dissociation of rTbHK1 multimers.  (Figure 4.2, top row, lanes 2 and 3).  
rTbHK2 behaved similarly (data not shown).   
Lonidamine, another TbHK inhibitor, did not disrupt TbHK1 oligomers under 
these conditions.  Incubation of TbHK1 with lonidamine in the presence or absence of 
ATP/Mg2+ or glucose had no impact on the ~300 kDa complex when compared to 
untreated TbHK1 (Figure 4.2, bottom lanes).  This is a similar result to what was 
observed with endogenous TbHK (Figure 4.1C, lane 3). 
Oligomer reassembly alters enzymatic activity of the complexes 
Myristate treatment liberates TbHK monomers.  In order to determine if the disassembly 
of TbHK oligomers was reversible, we incubated rTbHK1 and rTbHK2 with myristate in  
the presence of ATP/Mg2+ and then washed the myristate out of the sample by centrifuge 
filtration (The concept is illustrated in Figure 4.3A.).  Oligomers (Figure 4.3B) were 
treated with myristate (or DMSO carrier) and analyzed by native gel electrophoresis 
(Figure 4.3B) or by SDS-PAGE to confirm equal loading (lower panels in all sections of 
Figure 4.3B).  TbHKs treated with myristate were disassembled (Figure 4.3B, upper 
middle panel), when compared to samples treated with DMSO (Figure 4.3B, lower 
middle panel).  Myristate treatment, as anticipated, also inhibited TbHK1  >95% (data not 
shown).   
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Samples were then subjected to centrifuge filtration and washed exhaustively to 
remove myristate and then subjected to electrophoresis on native gels to explore 
reassembly.  Both rTbHK1 and rTbHK2 yielded reassembled ~300 kDa complexes after 
myristate disruption and centrifuge filtration.  These oligomers were similar to complexes 
found in untreated samples (Figure 4.3B, right panels).   
Following centrifuge filtration to remove myristate, rTbHK1 reassembled into 
oligomers with specific activity similar to untreated or DMSO treated rTbHK1 samples 
(Figure 4.3D left graph). Reassembled rTbHK2, on the other hand, remained inactive as 
was found in the untreated sample (Figure 4.3D left graph).  
 Mixing rTbHK1 and rTbHK2 (either with or without DMSO) had no impact on 
HK activity ([1], Figure 4.3D, left panel).  However, mixture of equal amounts of 
myristate-treated rTbHK1 and rTbHK2 prior to centrifugal filtration yielded enzyme 
activity with a ~3-fold increase in activity compared the controls (Figure 4.3D, left 
panel). Disassembly and reassembly were confirmed as before using native gel 
electrophoresis (data not shown). 
TbHK2 assembled with a catalytically inactive mutant TbHK1:S160A has HK activity 
To determine if the increase in mixed oligomer activity was due to a change in the 
specific activity of rTbHK1 or the result of some “activation” of rTbHK2 (which 
heretofore was inactive), rTbHK2 was reassembled with an inactive rTbHK1 variant, 
rTbHK1:S160A, that lacks phosphotransferase activity [1]First, the impact of centrifuge 
filtration and reassembly was assessed for rTbHK1:S160A.  This variant lacked 




           
 
Figure 4.3 TbHK oligomer reassembly reveals TbHK2 is an active hexokinase. (A.) A schematic illustrating the disassembly and reassembly of 
oligomeric rTbHKs.  (B.) Native gel (4%) and SDS-PAGE analysis of TbHKs prior to (left panels) incubation with or without DMSO or myristate.  
Samples were then analyzed to assess dissociation (middle), and again after centrifugal filtration (right). (C.) Schematic representation for assembly 






mixing rTbHK2 and rTbHK1:S160A resulted in detectable HK activity (Figure 4.3D, 
right panel), while mixing myristate treated rTbHK1:S160A with disassembled rTbHK1 
yielded a slight decrease in activity. 
Discussion 
T. brucei expresses two 98% identical HKs in both PF and BSF lifestages [6, 7]. 
Our initial investigations into the functions of the two proteins revealed that TbHK2 was 
a glycosomal protein that lacked detectable HK activity in vitro.  However, parasites 
lacking TbHK2 had altered morphology, retarded growth, and increased cellular HK 
activity, suggesting that the protein served some function for the parasites [1].  Recently, 
Albert et al. found through RNAi silencing of TbHK2 in BSF parasites that the gene is 
essential, with RNAi triggering a reduction in cellular glycolysis [8], again emphasizing 
the importance of this protein to the parasite. 
The altered rate of glycolysis in the RNAi BSF parasites suggests that TbHK2 
may be playing a role in the regulation of HK activity. Mammals have multiple HKs, 
with three ~100 kDa isoforms (Type I, II, and III) consisting of two monomer-like HKs 
fused together (which are likely the result of duplication and fusion of an ancestral 
HK[9]).  While the C-terminal domains are catalytically active, the N-terminal monomer-
like domains of the Type I and III isoforms are enzymatically inactive, serving to regulate 
the function of the enzyme by binding G6-P.  Authentic TbHK activity likely consists of  
a multimer of TbHK1 and 2, as the original activity purified with a molecular mass 
consistent with a hexameric complex [5].  TbHK2, like the inactive N-terminal domains 
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of Type I and III HKs, could regulate TbHK1 with which it is complexed, perhaps by 
altering the enzyme activity of TbHK1 after binding some regulatory molecule. 
We found previously that free fatty acids were inhibitors of TbHK1 [1], with 
myristate being the most potent identified to date.  Here, we have found that in addition 
to being an uncompetitive inhibitor of TbHK1, the fatty acid also disrupts oligomers of 
TbHKs.  Following disassembly, oligomer components could be reassembled to generate 
complexes with altered composition, which may have important consequences for 
activity.  Changes as a result of modulation of complex composition are found throughout 
biology.  Bax (a protein involved in apoptosis and cell signaling), for example, actively 
facilitates apoptosis via mitochondrial permeabilization as a homodimer, while being 
inactive when dimerized with other cellular components [10].  Authentic TbHK activity 
could be similarly influenced by changes in oligomer composition - as the ratio of 
complex components is changed during reassembly, the activity of the oligomer could 
change.  Indeed, the precedence for allosteric regulation in T. brucei by a catalytically 
inactive enzyme homolog has recently been established, with S-adenosylmethionine 
decarboxylase being activated by dimerization with an inactive homolog [11]. 
However, the story here is slightly different.  Disruption of recombinant 
oligomers isolated from E. coli and reassembly does indeed alter TbHK activity, but in a 
most surprising way.  Reassembly of the catalytically inactive TbHK2 with a catalytically 
incompetent TbHK1 variant (TbHK1S:160A, which has a conserved residue essential for 
transfer of the phosphoryl group altered[1]) yields an active TbHK2 protien.  
Interestingly, reassembly of the TbHK2 with itself does not activate the protein, 
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suggesting a specific interaction between TbHK2 and TbHK1 must occur for this 
activation to occur. 
Why myristate?  Myrisate is very important to the biology of the BSF parasite, 
serving as the sole fatty acid in the mature GPI anchor of the variant surface glycoprotein 
[12].  It is tempting to speculate that the large amount of myristate that is either taken up 
or synthesized by the BSF parasites for GPI biosynthesis might influence TbHK activity.  
GPI biosynthesis and maturation occurs on the endoplasmic reticulum (ER)[13], a 
compartment distinct from glycosomes.  However, there is communication between the 
two organelles, as some proteins transit from one compartment to the other.  In yeast, 
peroxisome biogenesis requires the anterograde movement of proteins from the ER to the 
organelle.  In trypanosomes, a GPI-specific phospholipase C has been found to 
translocate from glycosomes (which are specialized peroxisomes) to the ER in response 
to cellular stress [14].  Theses observations suggest that glycosomes may receive other 
cargo, including myristate, from the ER.  
Glycosomes also house enzymes that are responsible for phospholipid 
degradation and β-oxidation of fatty acids. Phospholipase A was identified in the 
glycosome by proteomics study [7] in BSF and PF trypanosomes. Phospholipase A 
catalyzes the hydrolysis of phopholipids separating the phosphorylated polar group from 
the fatty acids. β-oxidation of fatty acids has also been linked to the glycosome, as 
enzymatic activities associated with 2-enoyl CoA hydratase and hydroxyacyl-
dehydrogenase have been identified [15]. T. brucei also encodes a carnitine acetyl 
transferase that possesses a peroxisomal targeting sequence that may permit the protein to 
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be translocated into the glycosome [16]. The presence of components of these 
biochemical pathways provide further support for accumulation of free fatty acids, such 
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 Trypanosoma brucei, the causative agent of African trypanosomiasis, relies 
exclusively on glycolysis to produce ATP in the mammalian bloodstream. Hexokinases 
catalyze the initial step in glucose utilization the conversion of glucose to glucose-6-
phosphate. T.brucei expresses 98% identical hexokinases, TbHK1 and TbHK2. 
Recombinant TbHK1 was found to be an active hexokinase, while recombinant TbHK2 
was found to lack hexokinase activity. In this work, we set out to understand the 
biochemical differences between TbHK1 and TbHK2, and to use TbHK1 as a drug target 
to treat African trypanosomiasis. 
 The difference in the catalytic activity of the two hexokinases was attributed to 
the C-terminal tails of the polypeptides. Closer examination of this region revealed that 
the hexokinases had previously unidentified conserved motif in the C-terminal tail of the 
proteins. This motif, DGSGhGAA, was found in an ATP-binding domain known as the 
actin fold. TbHK2 does not have the complete motif, as the initial aspartic acid is replace 
by a glycine. To explore how the other differences in the C-terminal tail of TbHK1 
impacted catalysis, we employed site-directed mutagenesis to change individual residues 
in TbHK1 to their TbHK2 counterpart. We found that, in addition to D454, F462, M466, 
and N469 were all essential to catalysis. Interestingly loss of I458 and V468 
simultaneously also depleted TbHK1 of activity. Single variants of I458 and V468 were 
shown to have decreased affinity for ATP and fructose. This indicates that the C-terminal 
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tail is involved in both ATP binding and substrate specificity. We used molecular 
modeling to demonstrate that the C-terminal tail may impact the catalytic residue D214. 
In TbHK1, D214 sits upright in the active site with S456 pointed away from D214; 
conversely, TbHK2 modeling reveals that S456 is pointed toward the active site turning 
D214 downward away from the active site. Similar to TbHK2, modeling of TbHK1 
variant TbHK1:N469D demonstrates a positioning of S456 and D214 that resembles 
TbHK2. This is further evidence that the tail influences catalysis and substrate binding by 
rearranging the positioning of active site residues.  
 Given that TbHK1 was an active hexokinase, we used RNA interference to 
determine that TbHK1 was essential to the bloodstream form parasite. This is in 
agreement with the reliance of the parasite upon glycolysis for energy. Given that TbHK1 
is an essential gene, it is a useful target for drug development. Lonidamine is an anti-
cancer drug that targets tumor hexokinases, since hexokinase activity in T.brucei has 
similar characteristics as tumor hexokinases, we postulated that this may be a good drug 
to treat African trypanosomiasis. Indeed, we found recombinant TbHK1 was inhibited by 
lonidamine as was hexokinase activity in whole cell lysates. Additionally, we found that 
lonidamine was a potent trypanocidal agent with respect to bloodstream forms, and it was 
less effective against procyclic form parasites and procyclics adapted to low glucose 
media. To further demonstrate TbHK1 was a target of lonidamine, we overexpressed 
TbHK1 in the procyclic form parasites. Overexpression of TbHK1 was able to protect 
parasites from lonidamine treatment. These studies validated TbHK1 as a drug target for 
the treatment of African trypanosomiasis. 
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 In an attempt to identify metabolic regulators of TbHK1, we found that TbHK1 
was uncompetitively inhibited by free fatty acids. We then incubated myristate in the 
presence of recombinant TbHK1 in order to determine the impact on quaternary structure 
of the proteins. Endogenous TbHK and recombinant TbHK1 and TbHK2 are found as 
~300 kDa hexamers, and treatment with myristate in the presence of substrate 
disassembles the hexamer into monomeric (50 kDa) subunits as indicated by native gel 
and two-dimensional gel electrophoresis. Moreover, myristate induced disassembly of 
TbHK complexes is reversible. By removing myristate by centricon filtration, we were 
able to reassemble recombinant TbHK1 and TbHK2, even recovering catalytic activity of 
TbHK1. Since we were able to reassemble individual protein complexes, we decided to 
see if we could mix TbHK1 and TbHK2 in a hexameric form. We found that mixing 
equal amounts of TbHK1 and TbHK2 resulted in a 4-5 fold increase in hexokinase 
activity. To determine if the additional activity came from a change in specific activity of 
TbHK1 or activation of TbHK2, we made mixed hexamers of TbHK1 or TbHK2 with an 
inactive TbHK1 variant, TbHK1:S160A. We found that TbHK1 assembled with 
TbHK1:S160A had very little change in hexokinase activity; however, TbHK2 appears to 
have become active in the presence of TbHK1:S160A. These results indicate that TbHK2 
may be competent for hexokinase activity. 
 This work has progressed our understanding of T. brucei hexokinases. We have 
used molecular modeling and mutagenesis to determine that TbHK1 and TbHK2 may 
differ in substrate specificity and active site architecture. Our work on hexokinases has 
also led us to identify a new motif in an ATP-binding domain that is specific for 
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hexokinases. We have also improved our understanding of the quaternary structure of 
TbHK. By taking advantage of myristate-induced disassembly of our protein complexes, 
we were able to demonstrate that TbHK1 and TbHK2 can form a complex with one 
another; further, we demonstrated that TbHK2 is an active hexokinases that in complex 
with TbHK1 improved the catalytic activity of the complex. While this area requires 
more investigation, this represents the first time that TbHK has been shown to exist in a 
mixed complex. This also marks the first occasion that interaction of recombinant 
metabolic enzymes promotes activation of one of the proteins in the complex. 
 Finally, we have demonstrated that TbHK1 is a useful target for drug 
development. We have successful in our attempts to use a hexokinase inhibitor to inhibit 
TbHK1 and kill parasites. Given that TbHK2 is also an active hexokinase that is essential 
to the parasite, we hope that other compounds can be identified to inhibit TbHK1 and 













Oligonucleotide Primers Used in the Mutagenesis of TbHK1 and TbHK2 
Table A.1 Oligonucleotide Sequences for Primers Used in the Mutagenesis of the TbHK1 
and TbHK2 C-terminal Tails. 
Protein Sequence 
TbHK1 GATC AAG CTT TTA CTT GTC GTT CAC CAC CAT TG 
TbHK1:D470G GATC AAG CTT CCC GGG TTA CTT GCC GTT CAC CAC 
TbHK1:N469D GATC AAG CTT CCC GGG TTA CTT GTC GTC CAC CAC 
TbHK1:V468A GATC AAG CTT CTC GAG TTA CTT GTC GTT CGC CAC 
TbHK1:M466I GATC AAG CTT GAA TTC TTA CTT GTC GTT CAC CAC TAT TGC 
TbHK1:F462L GATC AAG CTT CAT ATG TTA CTT GTC GTT CAC CAC CAT TGC GGA AAT AAG TGC 
TbHK1:I458V AAG CTT GAG CTC TTA CTT GTC GTT CAC CAC CAT TGC GGA AAT AAA TGC AGC 
ACC AAC TC 
TbHK1:D454G GATC AAG CTT GTC GAC TTA CTT GTC GTT CAC CAC CAT TGC GGA AAT AAA TGC 
AGC ACC AAT TCC ACT GCC ACC C 
TbHK2 GATC AAG CTT TCA CTT CCC GTC AGC AAC GAT AG 
TbHK2:G470D GATC AAG CTT CCC GGG TCA CTT GTC GTC AGC AAC 
TbHK2:5TailMUT GATC AAG CTT CTC GAG TCA CTT GTC GCC AGC AAC 
TbHK2:D469N GATC AAG CTT CAT ATG TCA CTT CCC GCC AGC AAC 
TbHK2:I466M GAT CAA GCT TGA GCT CTC ACCT TCC CGT CAG CAA CCA TAG C 
TbHK2:L462F GAT CAA GCT TGT CGA CTC ACT TCC CGT CAG CAA CGA TAG CGG AGA TAA ATG C 
TbHK2:4TailMUT GAT CAA GCT TTC TAG ATC ACT TCC CGT TAG CAA CCA TAG CGG AGA TAA ATG C 
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 Table A.2 Mutagenic Primers for Phusion-based Site-Directed Mutagenesis of TbHK1 
and TbHK2 C-terminal Tails 
Protein Sequence 
TbHK1: S456A 5’-/5Phos/ GCA AAG GAT GGC GCT GGA ATT GGT-3’ 
TbHK1: S456A 5’-/5Phos/ GAG AAC GGC CCT GAC ATC-3’ 
TbHK2: G454D 5’-/5Phos/ CTC GCA AAG GAT GGC AGT GGT-3’ 
TbHK2: G454D 5’-/5Phos/ AAC GGC CCT GAC ATC GCA -3’ 
 
